

Facile functionalization at the C4 position of pyrimidine nucleosides *via* amide group activation with (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and biological evaluations of the products

Hari K. Akula, Hariprasad Kokatla, Graciela Andrei, Robert Snoeck, Dominique Schols,
Jan Balzarini, Lijia Yang and Mahesh K. Lakshman*

TABLE OF CONTENTS

Information	Page
General Experimental Considerations	S-4
General Procedures	S-4
Step 1 of two-step procedure (synthesis of 4 , 9 , and 10)	
Step 2 for aliphatic amines (synthesis of 6 , 11a–f , 12a–d , 13a–d)	S-4
1-(3,5-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl)-4-(morpholin-4-yl)-5-methyl-2(<i>1H</i>)-pyrimidinone (6)	S-5
3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>N</i> ,5-dimethyl-2'-deoxycytidine (11a)	S-5
<i>N</i> -Benzyl-3',5'-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-5-methyl-2'-deoxycytidine (11b)	S-6
3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>N,N</i> ,5-trimethyl-2'-deoxycytidine (11c)	S-6
3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>N,N</i> -diethyl-5-methyl-2'-deoxycytidine (11d)	S-7
1-(3,5-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl)-5-methyl-4-(pyrrolidin-1-yl)-2(<i>1H</i>)-pyrimidinone (11e)	S-7
1-(3,5-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(<i>1H</i>)-pyrimidinone (11f)	S-8
<i>N</i> -benzyl-3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2'-deoxycytidine (12a)	S-8
1-(3,5-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl)-4-(pyrrolidin-1-yl)-2(<i>1H</i>)-pyrimidinone (12b)	S-9
1-(3,5-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl)-4-(piperidin-1-yl)-2(<i>1H</i>)-pyrimidinone (12c)	S-10
1-(3,5-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl)-4-(morpholin-4-yl)-2(<i>1H</i>)-pyrimidinone (12d)	S-10
3'-Azido-5'- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>N,N</i> -diethyl-5-methyl-2',3'-dideoxycytidine (13a)	S-11
1-(3-Azido-5'- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(pyrrolidin-1-yl)-2(<i>1H</i>)-pyrimidinone (13b)	S-11
1-(3-Azido-5'- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(<i>1H</i>)-pyrimidinone (13c)	S-12
1-(3-Azido-5'- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(morpholin-4-yl)-2(<i>1H</i>)-pyrimidinone (13d)	S-12
Step 2 for <i>p</i> -toluidine (synthesis of 11g and 12e)	S-13
3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-5-methyl- <i>N</i> -(<i>p</i> -tolyl)-2'-deoxycytidine (11g)	S-13
3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>N</i> -(<i>p</i> -tolyl)-2'-deoxycytidine (12e)	S-14
Step 2 for thiols (synthesis of 11h and 11i)	S-14

3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>S</i> ⁴ -ethyl-4-thiothymidine (11h)	S-15
3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>S</i> ⁴ -benzyl-4-thiothymidine (11i)	S-15
Step 2 for NaSMe (synthesis of 11j)	S-16
3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>S</i> ⁴ -methyl-4-thiothymidine (11j)	S-16
1-(3,5-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-5-methyl-4-(3-oxido-1 <i>H</i> -benzotriazol-1-yl)-2(1 <i>H</i>)-pyrimidinone (17)	S-17
4-(1 <i>H</i> -Benzotriazol-1-yl)-1-(3,5-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-5-methyl-2(1 <i>H</i>)-pyrimidinone (18)	S-17
One-step procedure for aliphatic amines (synthesis of 6 , 11a-f , 12a-d , 13a-d)	S-18
3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>N</i> ,5-dimethyl-2'-deoxycytidine (11a)	S-18
One-step procedure for reaction with <i>p</i> -toluidine (synthesis of 11g and 12e)	S-19
One-step procedure for reaction with thiols (synthesis of 11i-j)	S-19
Procedure for reactions with methyl and cyclohexyl alcohols (synthesis of 14a , 14b , and 15)	S-20
3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>O</i> ⁴ -methylthymidine (14a)	S-20
3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>O</i> ⁴ -(cyclohex-1-yl)thymidine (14b)	S-20
3',5'-Di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>O</i> ⁴ -methyl-2'-deoxyuridine (15)	S-21
Procedure for reactions with allyl and benzyl alcohols (synthesis of 16a and 16b)	S-22
<i>O</i> ⁴ -Allyl-3'-azido-5'- <i>O</i> - <i>t</i> -butyldimethylsilyl-2',3'-dideoxythymidine (16a)	S-22
3'-Azido- <i>O</i> ⁴ -benzyl-5'- <i>O</i> - <i>t</i> -butyldimethylsilyl-2',3'-dideoxythymidine (16b)	S-23
Undesired 3',5'-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)- <i>O</i> ⁴ -ethylthymidine (19) obtained in a reaction with NaSMe	S-23
General procedure for the evaluation of various products formed with BOP from two commercial suppliers	S-24
Table 4: reactions with BOP from supplier 1 (Chem-Impex)	S-24
Table 4: reactions with BOP from supplier 2 (Sigma-Aldrich)	S-25
<i>O</i> ⁴ -(1 <i>H</i> -Benzotriazol-1-yl)-3',5'-di- <i>O</i> -(<i>t</i> -butyldimethylsilyl)thymidine (4)	S-25
Procedure for the deoxygenation of 17 to 18 with B ₂ (OH) ₄	S-26
Procedure for desilylation reactions	S-26
Method A (with <i>n</i> -Bu ₄ NF/THF for synthesis of 5 , 20b-i , 21a-d , 22a-d , 23b , 25a-b)	S-26
1-(2-Deoxy-β-D-ribofuranosyl)-5-methyl-4-(morpholin-4-yl)-2(1 <i>H</i>)-pyrimidinone (5)	S-27
<i>N</i> -Benzyl-5-methyl-2'-deoxycytidine (20b)	S-27
<i>N,N</i> ,5-Trimethyl-2'-deoxycytidine (20c)	S-28
<i>N,N</i> -Diethyl-5-methyl-2'-deoxycytidine (20d)	S-28
1-(2-Deoxy-β-D-ribofuranosyl)-5-methyl-4-(pyrrolidin-1-yl)-2(1 <i>H</i>)-pyrimidinone (20e)	S-29
1-(2-Deoxy-β-D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(1 <i>H</i>)-pyrimidinone (20f)	S-29
5-Methyl- <i>N</i> -(<i>p</i> -tolyl)-2'-deoxycytidine (20g)	S-30
<i>S</i> ⁴ -Ethyl-4-thiothymidine (20h)	S-30
<i>S</i> ⁴ -Benzyl-4-thiothymidine (20i)	S-31
<i>N</i> -Benzyl-2'-deoxycytidine (21a)	S-31

1-(2-Deoxy- β -D-ribofuranosyl)-4-(pyrrolidin-1-yl)-2(1 <i>H</i>)-pyrimidinone (21b)	S-32
1-(2-Deoxy- β -D-ribofuranosyl)-4-(piperidin-1-yl)-2(1 <i>H</i>)-pyrimidinone (21c)	S-32
1-(2-Deoxy- β -D-ribofuranosyl)-4-(morpholin-4-yl)-2(1 <i>H</i>)-pyrimidinone (21d)	S-33
3'-Azido- <i>N,N</i> -Diethyl-5-methyl-2',3'-dideoxycytidine (22a)	S-33
1-(3-Azido-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(pyrrolidin-1-yl)-2(1 <i>H</i>)-pyrimidinone (22b)	S-34
1-(3-Azido-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(1 <i>H</i>)-pyrimidinone (22c)	S-34
1-(3-Azido-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(morpholin-4-yl)-2(1 <i>H</i>)-pyrimidinone (22d)	S-35
<i>O</i> ⁴ -(Cyclohex-1-yl)thymidine (23b)	S-35
<i>O</i> ⁴ -Allyl-3'-azido-2',3'-dideoxythymidine (25a)	S-36
3'-Azido- <i>O</i> ⁴ -benzyl-2',3'-dideoxythymidine (25b)	S-36
Method B (with KF for synthesis of 20a and 21e)	S-37
<i>N</i> ,5-Dimethyl-2'-deoxycytidine (20a)	S-37
<i>N</i> -(<i>p</i> -Tolyl)-2'-deoxycytidine (21e)	S-37
Method C (with TASf for synthesis of 20j , 23a , and 24)	S-38
<i>S</i> ⁴ -Methyl-4-thiothymidine (20j)	S-38
<i>O</i> ⁴ -Methylthymidine (23a)	S-39
<i>O</i> ⁴ -Methyl-2'-deoxyuridine (24)	S-39
General Procedure For Reduction of 3'-Azido nucleosides To Amines (synthesis of compounds 26a-d)	S-40
3'-Amino- <i>N,N</i> -diethyl-5-methyl-2',3'-dideoxycytidine (26a)	S-40
1-(3-Amino-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(1 <i>H</i>)-pyrimidinone (26b)	S-41
1-(3-Amino-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(pyrrolidin-1-yl)-2(1 <i>H</i>)-pyrimidinone (26c)	S-41
1-(3-Amino-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(morpholin-4-yl)-2(1 <i>H</i>)-pyrimidinone (26d)	S-42
Antiviral activity assays	S-42
Cytostatic activity against immortalized cell lines	S-43

General Experimental Considerations

Reactions were conducted in screw-cap glass vials with Teflon-lined caps. Thin layer chromatography was performed on 200 μm aluminum-foil-backed silica gel plates. Column chromatography was performed using 200–300 mesh silica gel. In some cases the silica gel column had to be flushed twice with 5% Et_3N in hexanes before loading the crude material in order to neutralize silica gel (see details under the compound headings). THF was distilled from LiAlH_4 and then from Na prior to use. CH_3CN and 1,2-dimethoxyethane (DME) were distilled from CaH_2 . All other reagents were used as received from commercial suppliers. ^1H NMR spectra were obtained at 500 MHz and are referenced to the residual protonated solvent resonance. ^{13}C NMR spectra were obtained at 125 MHz and are referenced to the solvent resonance. Chemical shifts (δ) are reported in parts per million (ppm) and coupling constants (J) are in hertz (Hz). Standard abbreviations are used to designate resonance multiplicities.

General Procedures

*Step 1 of two-step procedure (synthesis of **4**, **9**, and **10**)*


To a 0.424 M solution of the nucleoside derivative (**2**: 0.212 mmol, **7**: 0.219 mmol, **8**: 0.262 mmol) in THF, BOP (2 equiv.) and DBU (2 equiv.) were added, and the mixture was stirred at room temperature for 30 min.

*Step 2 for aliphatic amines (synthesis of **6**, **11a–f**, **12a–d**, **13a–d**)*

To the reaction mixture from step 1, the appropriate amine (4 equiv.) was added and the reaction mixture was stirred at room temperature until consumption of the corresponding benzotriazolyl intermediate (**4**, **9** or **10**) occurred. The mixture was diluted with EtOAc (25 mL) and washed with deionized water (3 x 50 mL) followed by brine (15 mL). The organic


layer was dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. The crude material was purified by chromatography on a silica gel column using a suitable eluting solvent (see individual compound headings below).

1-(3,5-Di-*O*-(*t*-butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-4-(morpholin-4-yl)-5-methyl-2(1*H*)-pyrimidinone (6)



Chromatography on a silica gel column by sequential elution with 50% EtOAc in hexanes and EtOAc gave compound **6** (86.9 mg, 76%) as a sticky, white solid. *R_f* (SiO₂/EtOAc) = 0.32. ¹H NMR (500 MHz, acetone-*d*₆): δ 7.66 (s, 1H, H-6), 6.29 (t, *J* = 6.7 Hz, 1H, H-1'), 4.50 (dt, *J* = 2.8, 5.8 Hz, 1H, H-3'), 3.96 (app q, *J_{app}* ~ 3.2 Hz, 1H, H-4'), 3.90 (dd, *J* = 3.7, 11.3 Hz, 1H, H-5'), 3.86 (dd, *J* = 3.6, 11.4 Hz, 1H, H-5'), 3.70–3.66 (m, 4H, morpholinyl-CH₂), 3.65–3.61 (m, 4H, morpholinyl-CH₂), 2.30 (ddd, *J* = 2.9, 5.9, 13.3 Hz, 1H, H-2'), 2.15 (m, 4H, Me, and H-2'), 0.92 and 0.91 (2s, 18H, *t*-Bu), 0.13 and 0.12 (2s, 6H, SiMe), 0.11 and 0.10 (2s, 6H, SiMe). ¹³C NMR (125 MHz, acetone-*d*₆): δ 166.9, 156.5, 142.2, 104.8, 88.7, 86.4, 73.3, 67.1, 63.8, 48.3, 42.0, 26.3, 26.1, 18.9, 18.5, 18.0, -4.5, -4.7, -5.3. HRMS (ESI/TOF) *m/z* calculated for C₂₆H₄₉N₃O₅Si₂Na [*M* + Na]⁺: 562.3103, found 562.3107.


3',5'-Di-*O*-(*t*-butyldimethylsilyl)-N,5-dimethyl-2'-deoxycytidine (11a)



Chromatography on a silica gel column by sequential elution with EtOAc and 1% MeOH in EtOAc, gave compound **11a** (85.8 mg, 84%) as a white solid. *R_f* (SiO₂/EtOAc) = 0.17. ¹H NMR (500 MHz, CDCl₃): δ 7.49 (s, 1H, H-6), 6.38 (t, *J* = 6.5 Hz, 1H, H-1'), 5.25 (br s, 1H, NH), 4.36 (dt, *J* = 3.3, 6.4 Hz, 1H, H-3'), 3.90–3.87 (m, 2H, H-4' and H-5'), 3.77–3.74 (m, 1H, H-5'), 3.06 (d, *J* = 4.7 Hz, 3H, NMe), 2.39 (ddd, *J* = 3.7, 6.1, 13.3 Hz, 1H, H-2'), 1.97 (dt, *J* = 6.6, 13.3 Hz,


1H, H-2'), 1.88 (s, 3H, Me), 0.92 and 0.88 (2s, 18H, *t*-Bu), 0.10 and 0.09 (2s, 6H, SiMe), 0.06 and 0.05 (2s, 6H, SiMe). ¹³C NMR (125 MHz, CDCl₃): δ 163.8, 156.4, 136.5, 102.1, 87.6, 85.7, 71.9, 62.9, 42.1, 28.4, 26.1, 25.9, 18.5, 18.1, 13.3, -4.5, -4.7, -5.2, -5.3. HRMS (ESI/TOF) *m/z* calculated for C₂₃H₄₅N₃O₄Si₂Na [M + Na]⁺: 506.2841, found 506.2844.

***N*-Benzyl-3',5'-di-*O*-(*t*-butyldimethylsilyl)-5-methyl-2'-deoxycytidine (**11b**)**



Chromatography on a silica gel column by elution with 50% EtOAc in hexanes gave compound **11b** (85.7 mg, 72%) as a white solid. *R_f* (SiO₂/50% EtOAc in hexanes) = 0.24. ¹H NMR (500 MHz, acetone-*d*₆): δ 7.54 (s, 1H, H-6), 7.36 (d, *J* = 7.5 Hz, 2H, Ar-H), 7.28 (t, *J* = 7.5 Hz, 2H, Ar-H), 7.21 (t, *J* = 7.3 Hz, 1H, Ar-H), 7.06–6.98 (m, 1H, NH), 6.35 (dd, *J* = 6.0, 7.7 Hz, 1H, H-1'), 4.70–4.68 (m, 2H, NCH₂), 4.50 (dt, *J* = 2.8, 5.7 Hz, 1H, H-3'), 3.92 (app q, *J_{app}* ~ 3.1 Hz, 1H, H-4'), 3.90–3.84 (m, 2H, H-5'), 2.24 (ddd, *J* = 2.7, 5.8, 13.1 Hz, 1H, H-2'), 2.08–2.04 (m, 1H, H-2'), 1.99 (s, 3H, Me), 0.95 and 0.92 (2s, 18H, *t*-Bu), 0.15 and 0.14 (2s, 6H, SiMe), 0.13 (s, 6H, SiMe). ¹³C NMR (125 MHz, acetone-*d*₆): δ 164.1, 156.1, 140.6, 137.9, 128.9, 128.6, 127.5, 102.6, 88.3, 86.1, 73.6, 64.0, 44.6, 42.0, 26.4, 26.2, 18.9, 18.6, 13.6, -4.4, -4.6, -5.1, -5.2. HRMS (ESI/TOF) *m/z* calculated for C₂₉H₄₉N₃O₄Si₂Na [M + Na]⁺: 582.3154, found 582.3156.


3',5'-Di-*O*-(*t*-butyldimethylsilyl)-*N,N*,5-trimethyl-2'-deoxycytidine (11c**)**



Chromatography on a silica gel column by sequential elution with 50% EtOAc in hexanes and EtOAc gave compound **11c** (79.9 mg, 76%) as a viscous, colorless liquid. *R_f* (SiO₂/EtOAc) = 0.35. ¹H NMR (500 MHz, CDCl₃): δ 7.48 (s, 1H, H-6), 6.34 (t, *J* = 6.4 Hz, 1H, H-1'), 4.35 (dt, *J* = 3.3, 6.4 Hz, 1H, H-3'), 3.90–3.86 (m, 2H, H-4' and H-5'), 3.75 (dd, *J* = 2.5, 11.1 Hz, 1H, H-5'), 3.13 (s, 6H, NMe₂), 2.37 (ddd, *J* = 3.8, 5.9, 13.3 Hz, 1H, H-2'), 2.13 (s, 3H, Me), 1.95 (dt,


$J = 6.6, 13.3$ Hz, 1H, H-2'), 0.91 and 0.87 (2s, 18H, *t*-Bu), 0.10 and 0.09 (2s, 6H, SiMe), 0.05 and 0.04 (2s, 6H, SiMe). HRMS (ESI/TOF) m/z calculated for $C_{24}H_{47}N_3O_4Si_2Na$ $[M + Na]^+$: 520.2997, found 520.2974. The 1H NMR spectrum matches that of the material reported (H. Yamada, K. Tanabe, T. Ito, S.-I. Nishimoto, *Chem. Eur. J.*, 2008, **14**, 10453–10461).

3',5'-Di-*O*-(*t*-butyldimethylsilyl)-*N,N*-diethyl-5-methyl-2'-deoxycytidine (**11d**)



Chromatography on a silica gel column by sequential elution with 25% EtOAc in hexanes and 50% EtOAc in hexanes gave compound **11d** (86.9 mg, 78%) as a viscous, colorless liquid. R_f (SiO_2 /50% EtOAc in hexanes) = 0.24. 1H NMR (500 MHz, $CDCl_3$): δ 7.43 (s, 1H, H-6), 6.35 (t, $J = 6.5$ Hz, 1H, H-1'), 4.37 (dt, $J = 3.2, 6.3$ Hz, 1H, H-3'), 3.90–3.86 (m, 2H, H-4' and H-5'), 3.76 (dd, $J = 2.0, 11.2$ Hz, 1H, H-5'), 3.60–3.52 (m, 4H, NCH_2), 2.38 (ddd, $J = 3.8, 5.7, 13.2$ Hz, 1H, H-2'), 2.13 (s, 3H, Me), 1.99 (dt, $J = 6.7, 13.3$ Hz, 1H, H-2'), 1.20 (t, $J = 7.0$ Hz, 6H, Me), 0.92 and 0.88 (2s, 18H, *t*-Bu), 0.10 (s, 6H, SiMe), 0.06 and 0.05 (2s, 6H, SiMe). ^{13}C NMR (125 MHz, $CDCl_3$): δ 164.5, 155.4, 140.7, 102.2, 87.7, 85.8, 71.9, 62.9, 43.8, 42.2, 26.2, 26.0, 19.0, 18.6, 18.2, 14.0, -4.3, -4.7, -5.1, -5.2. HRMS (ESI/TOF) m/z calculated for $C_{26}H_{52}N_3O_4Si_2$ $[M + H]^+$: 526.3491, found 526.3499.


1-(3,5-Di-*O*-(*t*-butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl)-5-methyl-4-(pyrrolidin-1-yl)-2(1*H*)-pyrimidinone (**11e**)



Chromatography on a silica gel column by sequential elution with 40% EtOAc in hexanes and 75% EtOAc in hexanes gave compound **11e** (83.5 mg, 75%) as a viscous, colorless liquid. R_f (SiO_2 /EtOAc) = 0.48. 1H NMR (500 MHz, $CDCl_3$): δ 7.38 (s, 1H, H-6), 6.26 (t, $J = 6.5$ Hz, 1H, H-1'), 4.33 (dt, $J = 3.1, 6.1$ Hz, 1H, H-3'), 3.86 (app q, $J_{app} \sim 2.9$ Hz, 1H, H-4'), 3.82 (dd, $J =$

2.8, 11.3 Hz, 1H, H-5'), 3.73–3.71 (m, 5H, H-5' and N(CH₂)₂), 2.27 (ddd, *J* = 3.5, 6.0, 13.3 Hz, 1H, H-2'), 2.16 (s, 3H, Me), 1.95 (dt, *J* = 6.7, 13.4 Hz, 1H, H-2'), 1.92–1.84 (m, 4H, CH₂), 0.89 and 0.84 (2s, 18H, *t*-Bu), 0.07 and 0.06 (2s, 6H, SiMe), 0.03 (s, 6H, SiMe). ¹³C NMR (125 MHz, acetone-*d*₆): δ 163.4, 155.1, 140.1, 102.6, 88.2, 85.9, 73.6, 64.0, 49.7, 41.9, 26.3, 26.2, 25.9 (br), 18.9, 18.6, 18.2, –4.5, –4.6, –5.2, –5.3. HRMS (ESI/TOF) *m/z* calculated for C₂₆H₄₉N₃O₄Si₂Na [M + Na]⁺: 546.3154, found 546.3159.


1-(3,5-Di-*O*-(*t*-butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(1*H*)-pyrimidinone (11f)



Chromatography on a silica gel column by sequential elution with 25% EtOAc in hexanes and 50% EtOAc in hexanes gave compound **11f** (85.8 mg, 75%) as a viscous, colorless liquid. *R_f* (SiO₂/50% EtOAc in hexanes) = 0.28. ¹H NMR (500 MHz, CDCl₃): δ 7.53 (s, 1H, H-6), 6.35 (t, *J* = 6.5 Hz, 1H, H-1'), 4.36 (dt, *J* = 3.3, 6.4 Hz, 1H, H-3'), 3.92–3.86 (m, 2H, H-4' and H-5'), 3.75 (dd, *J* = 1.8, 10.7 Hz, 1H, H-5'), 3.55–3.50 (br m, 4H, NCH₂), 2.39 (ddd, *J* = 3.9, 6.1, 13.3 Hz, 1H, H-2'), 2.06 (s, 3H, Me), 1.99 (dt, *J* = 6.6, 13.3 Hz, 1H, H-2'), 1.69–1.58 (br m, 6H, (CH₂)₃), 0.92 and 0.88 (2s, 18H, *t*-Bu), 0.10 and 0.09 (2s, 6H, SiMe), 0.06 and 0.05 (2s, 6H, SiMe). ¹³C NMR (125 MHz, CDCl₃): δ 166.8, 155.6, 140.8, 103.4, 87.6, 85.8, 71.7, 62.8, 48.4, 42.1, 26.2, 26.1, 25.9, 24.6, 18.5, 18.2, 18.1, –4.4, –4.8, –5.2, –5.3. HRMS (ESI/TOF) *m/z* calculated for C₂₇H₅₁N₃O₄Si₂Na [M + Na]⁺: 560.3310, found 560.3315.


***N*-benzyl-3',5'-Di-*O*-(*t*-butyldimethylsilyl)-2'-deoxycytidine (12a)**

Chromatography on a silica gel column by sequential elution with 25% EtOAc in hexanes and 60% EtOAc in hexanes gave compound **12a** (93.6 mg, 78%) as a viscous, colorless



liquid. R_f (SiO_2 /50% EtOAc in hexanes) = 0.20. ^1H NMR (500 MHz, acetone- d_6): δ 7.83 (d, J = 7.5 Hz, 1H, H-6), 7.36 (d, J = 7.2 Hz, 2H, Ar-H), 7.31 (t, J = 7.5 Hz, 2H, Ar-H), 7.24 (t, J = 7.2 Hz, 1H, Ar-H), 7.18–7.17 (br t, J = 6.0 Hz, 1H, NH), 6.30 (t, J = 6.3 Hz, 1H, H-1'), 5.83 (d, J = 7.5 Hz, 1H, H-5), 4.63–4.60 (m, 2H, NCH_2), 4.52 (dt, J = 3.7, 6.0 Hz, 1H, H-3'), 3.92–3.89 (m, 2H, H-4' and H-5'), 3.87–3.84 (m, 1H, H-2'), 2.30 (ddd, J = 4.2, 6.1, 13.2 Hz, 1H, H-2'), 2.11 (dt, J = 6.5, 13.1 Hz, 1H, H-2'), 0.94 and 0.92 (2s, 18H, *t*-Bu), 0.13 (s, 12H, SiMe). ^{13}C NMR (125 MHz, acetone- d_6): δ 164.7, 156.4, 140.5, 140.0, 129.1, 128.6, 127.7, 95.5, 88.0, 86.2, 72.5, 63.4, 44.6, 42.2, 26.3, 26.2, 18.9, 18.5, –4.4, –4.6, –5.2, –5.3. HRMS (ESI/TOF) m/z calculated for $\text{C}_{28}\text{H}_{47}\text{N}_3\text{O}_4\text{Si}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$: 568.2997, found 568.2996.


1-(3,5-Di-*O*-(*t*-butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl)-4-(pyrrolidin-1-yl)-2(1*H*)-pyrimidinone (12b)



Chromatography on a silica gel column by sequential elution with 50% EtOAc in hexanes and EtOAc, gave compound **12b** (79.7 mg, 71%) as a white solid. R_f (SiO_2 /EtOAc) = 0.23. ^1H NMR (500 MHz, CDCl_3): δ 7.94 (d, J = 7.6 Hz, 1H, H-6), 6.30 (t, J = 5.7 Hz, 1H, H-1'), 5.60 (d, J = 7.6 Hz, 1H, H-5), 4.36 (app q, $J_{\text{app}} \sim 5.7$ Hz, 1H, H-3'), 3.91 (dd, J = 2.4, 11.3 Hz, 1H, H-5'), 3.86 (dt, J = 2.4, 4.9 Hz, 1H, H-4'), 3.75 (dd, J = 2.2, 11.3 Hz, 1H, H-5'), 3.66 (t, J = 6.8 Hz, 2H, NCHH), 3.38 (t, J = 6.8 Hz, 2H, NCHH), 2.40 (dt, J = 6.4, 13.1 Hz, 1H, H-2'), 2.11–2.06 (m, 1H, H-2'), 2.04–1.97 (m, 2H, CH_2), 1.96–1.87 (m, 2H, CH_2), 0.92 and 0.86 (2s, 18H, *t*-Bu), 0.10 and 0.09 (2s, 6H, SiMe), 0.04 and 0.03 (2s, 6H, SiMe). ^{13}C NMR (125 MHz, acetone- d_6): δ 162.3, 155.7, 141.2, 93.0, 88.2, 86.3, 72.8, 63.6, 47.3, 42.3, 26.4, 26.2, 25.3, 18.9, 18.6, –4.4,

–4.6, –5.2, –5.3. HRMS (ESI/TOF) m/z calculated for $C_{25}H_{47}N_3O_4Si_2Na$ $[M + Na]^+$: 532.2997, found 532.2994.

1-(3,5-Di-*O*-(*t*-butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl)-4-(piperidin-1-yl)-2(1*H*)-pyrimidinone (12c)




Chromatography on a silica gel column by sequential elution with 30% EtOAc in hexanes and 60% EtOAc in hexanes, gave compound **12c** (86.4 mg, 75%) as a white solid. R_f (SiO_2 /100% EtOAc) = 0.57.

1H NMR (500 MHz, acetone- d_6): δ 7.91 (d, J = 7.8 Hz, 1H, H-6), 6.30 (t, J = 6.4 Hz, 1H, H-1'), 6.28 (d, J = 7.8 Hz, 1H, H-5), 4.52 (dt, J = 3.2, 6.1 Hz, 1H, H-3'), 3.94–3.88 (m, 3H, H-4' and H-5'), 3.85 (dd, J = 2.9, 11.2 Hz, 1H, H-5'), 3.81–3.49 (br m, 4H, NCH_2), 2.30 (ddd, J = 3.9, 6.0, 13.2 Hz, 1H, H-2'), 2.21 (dt, J = 6.5, 13.2 Hz, 1H, H-2'), 1.71–1.64 (m, 2H, CH_2), 1.59–1.51 (br m, 4H, CH_2), 0.93 and 0.91 (2s, 18H, *t*-Bu), 0.13 (s, 6H, SiMe), 0.12 and 0.11 (2s, 6H, SiMe). ^{13}C NMR (125 MHz, acetone- d_6): δ 163.1, 156.7, 141.7, 92.4, 88.3, 86.3, 72.8, 63.6, 47.0 (br), 45.2 (br), 42.2, 26.6 (br), 26.3, 26.1, 25.1, 18.9, 18.5, –4.5, –4.6, –5.2, –5.3. HRMS (ESI/TOF) m/z calculated for $C_{26}H_{49}N_3O_4Si_2Na$ $[M + Na]^+$: 546.3154, found 546.3159.


1-(3,5-Di-*O*-(*t*-butyldimethylsilyl)-2-deoxy- β -D-ribofuranosyl)-4-(morpholin-4-yl)-2(1*H*)-pyrimidinone (12d)

Chromatography on a silica gel column by sequential elution with 50% EtOAc in hexanes followed by EtOAc, gave compound **12d** (87.5 mg, 76%) as a colorless liquid. R_f (SiO_2 /EtOAc) = 0.48. 1H NMR (500 MHz, acetone- d_6): δ 7.93 (d, J = 7.8 Hz, 1H, H-6), 6.27 (t, J = 6.3 Hz, 1H, H-1'), 6.01 (d, J = 7.8 Hz, 1H, H-5), 4.51 (dt, J = 3.5, 5.7 Hz, 1H, H-3'), 3.93–3.89 (m, 2H, H-4' and H-5'), 3.85 (dd, J = 2.4, 10.8 Hz, 1H, H-5'), 3.66 (br s, 8H, $O(CH_2)_2$ and



$N(CH_2)_2$), 2.31 (ddd, $J = 4.1, 6.0, 13.2$ Hz, 1H, H-2'), 2.18 (dt, $J = 6.5, 13.1$ Hz, 1H, H-2'), 0.94 and 0.92 (2s, 18H, *t*-Bu), 0.13 and 0.12 (2s, 12H, SiMe). ^{13}C NMR (125 MHz, $CDCl_3$): δ 164.0, 155.3, 142.1, 91.2, 88.3, 86.4, 72.8, 67.1, 63.6, 45.2 (br), 42.4, 26.4, 26.2, 18.9, 18.6, -4.4, -4.6, -5.3. HRMS (ESI/TOF) m/z calculated for $C_{25}H_{47}N_3O_5Si_2Na$ [$M + Na$] $^+$: 548.2946, found 548.2950.


3'-Azido-5'-O-(*t*-butyldimethylsilyl)-*N,N*-diethyl-5-methyl-2',3'-dideoxycytidine (**13a**)



Chromatography on a silica gel column by sequential elution with 25% EtOAc in hexanes and 75% EtOAc in hexanes gave compound **13a** (65.4 mg, 57%) as colorless, viscous liquid. R_f (SiO_2 /EtOAc) = 0.35. 1H NMR (500 MHz, acetone- d_6): δ 7.52 (s, 1H, H-6), 6.18 (t, $J = 6.5$ Hz, 1H, H-1'), 4.43 (dt, $J = 3.8, 7.3$ Hz, 1H, H-3'), 4.00–3.94 (m, 2H, H-4' and H-5'), 3.92 (dd, $J = 3.4, 11.1$ Hz, 1H, H-5'), 3.58 (q, $J = 7.0$ Hz, 4H, NCH_2), 2.43 (ddd, $J = 4.6, 6.1, 13.6$ Hz, 1H, H-2'), 2.34 (dt, $J = 6.9, 13.7$ Hz, 1H, H-2'), 2.19 (s, 3H, Me), 1.19 (t, $J = 7.0$ Hz, 6H, Me), 0.94 (s, 9H, *t*-Bu), 0.15 (s, 6H, SiMe). ^{13}C NMR (125 MHz, acetone- d_6): δ 165.0, 155.2, 141.6, 102.7, 86.1, 85.2, 64.0, 62.1, 44.2, 38.6, 26.3, 18.9, 18.8, 14.0, -5.2, -5.3. HRMS (ESI/TOF) m/z calculated for $C_{20}H_{36}N_6O_3SiNa$ [$M + Na$] $^+$: 459.2510, found 459.2519.

1-(3-Azido-5'-O-(*t*-butyldimethylsilyl)-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(pyrrolidin-1-yl)-2(1*H*)-pyrimidinone (**13b**)


Chromatography on a silica gel column using EtOAc gave compound **13b** (60.4 mg, 53%) as a viscous, colorless liquid. R_f (SiO_2 /EtOAc) = 0.27. 1H NMR (500 MHz, acetone- d_6): δ 7.43 (s, 1H, H-6), 6.19 (t, $J = 6.6$ Hz, 1H, H-1'), 4.42 (dt, $J = 3.8, 7.4$ Hz, 1H, H-3'), 3.97–3.90 (m, 3H, H-4', H-5', and H-5'), 3.73–3.63 (br m, 4H, NCH_2), 2.39 (ddd, $J = 4.4, 6.3, 13.6$ Hz, 1H, H-2'),



2.30 (dt, $J = 6.9, 13.7$ Hz, 1H, H-2'), 2.20 (d, $J = 0.9$ Hz, 3H, Me), 1.93-1.85 (m, 4H, CH₂), 0.94 (s, 9H, *t*-Bu), 0.15 (s, 6H, SiMe). ¹³C NMR (125 MHz, acetone-*d*₆): δ 163.6, 154.9, 140.2, 102.7, 85.9, 85.0, 64.1, 62.1, 49.8, 38.5, 26.3, 25.9 (br), 18.9, 18.2, -5.2, -5.3. HRMS (ESI/TOF) m/z

calculated for C₂₀H₃₄N₆O₃SiNa [M + Na]⁺: 457.2354, found 457.2365.

1-(3-Azido-5-*O*-(*t*-butyldimethylsilyl)-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(1H)-pyrimidinone (13c)




Chromatography on a silica gel column by sequential elution with 50% EtOAc in hexanes and EtOAc gave compound **13c** (74.1 mg, 63%) as a colorless, viscous liquid. R_f (SiO₂/EtOAc) = 0.55. ¹H NMR (500 MHz, acetone-*d*₆): δ 7.57 (d, $J = 0.7$ Hz, 1H, H-6), 6.16 (t, $J = 6.5$

Hz, 1H, H-1'), 4.43 (dt, $J = 4.1, 7.2$ Hz, 1H, H-3'), 4.00–3.95 (m, 2H, H-4' and H-5'), 3.92 (dd, $J = 3.3, 11.2$ Hz, 1H, H-5), 3.51 (t, $J = 5.2$ Hz, 4H, NCH₂), 2.44 (ddd, $J = 4.5, 6.3, 13.7$ Hz, 1H, H-2'), 2.33 (dt, $J = 6.9, 13.7$ Hz, 1H, H-2'), 2.10 (d, $J = 0.7$ Hz, 3H, Me), 1.70–1.64 (m, 2H, CH₂), 1.64–1.58 (m, 4H, CH₂), 0.94 (s, 9H, *t*-Bu), 0.15 (s, 6H, SiMe). ¹³C NMR (125 MHz, acetone-*d*₆): δ 167.4, 155.1, 141.9, 103.6, 86.2, 85.2, 64.0, 62.0, 48.8, 38.7, 26.7, 26.3, 25.3, 18.9, 18.0, -5.2, -5.3. HRMS (ESI/TOF) m/z calculated for C₂₁H₃₆N₆O₃SiNa [M + Na]⁺: 471.2510, found 471.2506.

1-(3-Azido-5-*O*-(*t*-butyldimethylsilyl)-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(morpholin-4-yl)-2(1H)-pyrimidinone (13d)

Chromatography on a silica gel column by sequential elution with 50% EtOAc in hexanes and EtOAc, gave compound **13d** (67.3 mg, 57%) as a colorless liquid. R_f (SiO₂/EtOAc) = 0.27. ¹H NMR (500 MHz, acetone-*d*₆): δ 7.62 (s, 1H, H-6), 6.15 (t, $J = 6.4$ Hz, 1H, H-1'), 4.43



(dt, $J = 4.3, 7.1$ Hz, 1H, H-3'), 4.01 (app q, $J_{app} \sim 3.7$ Hz, 1H, H-4'), 3.97 (dd, $J = 3.5, 11.3$ Hz, 1H, H-5'), 3.93 (dd, $J = 3.4, 11.3$ Hz, 1H, H-5), 3.73–3.65 (m, 4H, morpholinyl-CH₂), 3.62–3.52 (m, 4H, morpholinyl-CH₂), 2.47 (ddd, $J = 4.5, 6.3, 13.7$ Hz, 1H, H-2'), 2.34 (dt, $J = 6.9, 13.7$ Hz, 1H, H-2'), 2.11 (s, 3H, Me), 0.94 (s, 9H, *t*-Bu), 0.15 (s, 6H, SiMe).


¹³C NMR (125 MHz, acetone-*d*₆): δ 167.5, 155.0, 142.3, 103.5, 86.4, 85.4, 67.3, 64.0, 62.0, 48.4, 38.7, 26.3, 18.9, 17.8, –5.2. HRMS (ESI/TOF) m/z calculated for C₂₀H₃₄N₆O₄SiNa [M + Na]⁺: 473.2303, found 473.2302.

Step 2 for *p*-toluidine (synthesis of **11g** and **12e**)

The reaction mixture from step 1 was evaporated on a rotary evaporator and dried under high vacuum for 10 min. The residual material was dissolved in EtOH (2 mL), *p*-toluidine (2 equiv.) and iPr₂NEt (2 equiv.) were added, and the mixture was stirred at 50 °C for 16 h. The reaction mixture was cooled then diluted with EtOAc (25 mL), washed with deionized water (3 x 50 mL), and brine (15 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. The crude material was purified by chromatography on a silica gel column using a suitable eluting solvent (see individual compound headings below).

3',5'-Di-*O*-(*t*-butyldimethylsilyl)-5-methyl-*N*-(*p*-tolyl)-2'-deoxycytidine (**11g**)


Chromatography on a silica gel column by sequential elution with 15% EtOAc in hexanes and 40% EtOAc in hexanes, gave compound **11g** (73.6 mg, 62%) as a light-brown solid. R_f (SiO₂/25% EtOAc in hexanes) = 0.14. ¹H NMR (500 MHz, CDCl₃): δ 7.54 (br s, 3H, H-6, Ar-H), 7.36 (d, $J = 8.1$ Hz, 2H, Ar-H), 6.67–6.40 (m, 1H, NH), 6.34 (t, $J = 6.4$ Hz, 1H, H-1'), 4.37 (dt, $J = 3.3, 6.3$ Hz, 1H, H-3'), 3.92–3.89 (m, 2H, H-4' and H-5'), 3.77 (dd, $J = 2.3, 11.2$ Hz, 1H,



H-5'), 2.42 (br s, 1H, H-2'), 2.33 (s, 3H, ArMe), 2.03–1.98 (m, 4H, H-2', Me), 0.93 and 0.89 (2s, 18H, *t*-Bu), 0.12 and 0.11 (2s, 6H, SiMe), 0.07 and 0.06 (2s, 6H, SiMe). ^{13}C NMR (125 MHz, CDCl_3): δ 161.2, 155.6, 137.9, 135.8, 134.1, 129.6, 121.9, 102.2, 87.7, 86.0, 71.8, 62.9, 42.1, 26.1, 25.9, 21.0, 18.6, 18.2, 13.8, -4.4, -4.7, -5.2.

HRMS (ESI/TOF) m/z calculated for $\text{C}_{29}\text{H}_{50}\text{N}_3\text{O}_4\text{Si}_2$ $[\text{M} + \text{H}]^+$: 560.3334, found 560.3311.

3',5'-Di-*O*-(*t*-butyldimethylsilyl)-*N*-(*p*-tolyl)-2'-deoxycytidine (**12e**)



Chromatography on a silica gel column by sequential elution with 20% EtOAc in hexanes and 40% EtOAc in hexanes gave compound **12e** (74.1 mg, 64%), as a light-brown solid. R_f (SiO_2 /50% EtOAc in hexanes) = 0.24. ^1H NMR (500 MHz, CDCl_3): δ 8.46–8.08 (br, 1H, NH), 8.19 (d, J = 7.4 Hz, 1H, H-6), 7.52–7.22 (br m, 2H, Ar-H), 7.22–7.11 (m, 2H, Ar-H), 6.32–6.27 (m, 1H, H-1'), 5.88 (d, J = 7.4 Hz, 1H, H-5), 4.41–4.34 (m, 1H, H-3'), 3.94–3.87 (m, 2H, H-4' and H-5'), 3.77 (d, J = 11.5 Hz, 1H, H-5'), 2.49–2.40 (m, 1H, H-2'), 2.34 (s, 3H, ArMe), 2.16–2.08 (m, H-2), 0.90 and 0.88 (2s, 18H, *t*-Bu), 0.09 (s, 6H, SiMe), 0.06 (s, 6H, SiMe). ^{13}C NMR (125 MHz, CDCl_3): δ 163.9 (br), 155.8 (br), 141.7 (br), 135.3 (br), 130.0, 124.1 (br), 92.1 (br), 87.5, 86.2, 70.4, 62.1, 42.3, 26.1, 25.9, 21.1, 18.5, 18.1, -4.4, -4.8, -5.3, -5.4.


HRMS (ESI/TOF) m/z calculated for $\text{C}_{28}\text{H}_{48}\text{N}_3\text{O}_4\text{Si}_2$ $[\text{M} + \text{H}]^+$: 546.3178, found 546.3173.

Step 2 for thiols (synthesis of **11h** and **11i**)

The reaction mixture from step 1 was evaporated on a rotary evaporator and dried under high vacuum for 10 min. The residual material was dissolved in dry DME (2 mL), the appropriate thiol (0.425 mmol, 2 equiv.) and Cs_2CO_3 (138.1 mg, 0.425 mmol, 2 equiv.) were

added, and the mixture was stirred at room temperature until consumption of **9** occurred. The reaction mixture was then diluted with EtOAc (25 mL), washed with deionized water (3 x 50 mL), and brine (15 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. The crude material was purified by chromatography on a neutralized silica gel column using a suitable eluting solvent (see individual compound headings below and the General Experimental Considerations).


3',5'-Di-*O*-(*t*-butyldimethylsilyl)-*S*⁴-ethyl-4-thiothymidine (**11h**)



Chromatography on a neutralized silica gel column by sequential elution with 5% EtOAc in hexanes and 10% EtOAc in hexanes gave compound **11h** (74.4 mg, 68%) as a white solid. *R_f* (SiO₂/50% EtOAc in hexanes) = 0.75. ¹H NMR (500 MHz, acetone-*d*₆): δ 7.73 (d, *J* = 0.4 Hz, 1H, H-6), 6.20 (t, *J* = 6.6 Hz, 1H, H-1'), 4.52 (dt, *J* = 2.9, 5.8 Hz, 1H, H-3'), 4.02 (app q, *J_{app}* ~ 3.1 Hz, 1H, H-4'), 3.93 (dd, *J* = 3.6, 11.4 Hz, 1H, H-5'), 3.89 (dd, *J* = 3.3, 11.4 Hz, 1H, H-5'), 3.15 (q, *J* = 7.4 Hz, 2H, SCH₂), 2.43 (ddd, *J* = 3.0, 5.9, 13.3 Hz, 1H, H-2'), 2.15 (ddd, *J* = 6.1, 7.2, 13.3 Hz, 1H, H-2'), 1.99 (d, *J* = 0.6 Hz, 3H, Me), 1.31 (t, *J* = 7.3 Hz, 3H, Me), 0.93 and 0.92 (2s, 18H, *t*-Bu), 0.14 (2s, 6H, SiMe), 0.13 (2s, 6H, SiMe). ¹³C NMR (125 MHz, acetone-*d*₆): δ 177.6, 153.5, 138.4, 111.2, 88.9, 87.3, 73.3, 63.7, 42.5, 26.3, 26.2, 24.3, 18.9, 18.5, 14.5, 14.3, -4.5, -4.7, -5.3. HRMS (ESI/TOF) *m/z* calculated for C₂₄H₄₆N₂O₄SSi₂Na [M + Na]⁺: 537.2609, found 537.2611.

3',5'-Di-*O*-(*t*-butyldimethylsilyl)-*S*⁴-benzyl-4-thiothymidine (**11i**)

Chromatography on a neutralized silica gel column by sequential elution with 5% EtOAc in hexanes, 7% EtOAc in hexanes, and 10% EtOAc in hexanes gave compound **11i** (85.6 mg, 70%) as a white solid. *R_f* (SiO₂/25% EtOAc in hexanes) = 0.57. ¹H NMR (500 MHz, acetone-




d_6): δ 7.77 (s, 1H, H-6), 7.46 (d, J = 7.2 Hz, 2H, Ar-H), 7.31 (t, J = 7.4 Hz, 2H, Ar-H), 7.25 (t, J = 7.3 Hz, 1H, Ar-H), 6.23 (t, J = 6.6 Hz, 1H, H-1'), 4.53 (dt, J = 2.9, 5.8 Hz, 1H, H-3'), 4.45 (s, 2H, SCH₂), 4.03 (app q, J_{app} ~ 3.2 Hz, 1H, H-4'), 3.94 (dd, J = 3.6, 11.4 Hz, 1H, H-5'), 3.89 (dd, J = 3.3, 11.4 Hz, 1H, H-5'), 2.45 (ddd, J = 3.1, 5.9, 13.3 Hz, 1H, H-2'), 2.17 (ddd, J = 6.2, 7.1, 13.3 Hz, 1H, H-2'), 1.99 (s, 3H, Me), 0.93 (2s, 18H, *t*-Bu), 0.14 (2s, 12H, SiMe). ¹³C NMR (125 MHz, acetone-*d*₆): δ 177.1, 153.5, 138.9, 138.3, 130.1, 129.3, 128.0, 111.1, 89.1, 87.5, 73.4, 63.8, 42.5, 34.1, 26.3, 26.2, 18.9, 18.5, 14.3, -4.4, -4.6, -5.2. HRMS (ESI/TOF) m/z calculated for C₂₉H₄₈N₂O₄SSi₂Na [M + Na]⁺: 599.2766, found 599.2764.

Step 2 for NaSMe (synthesis of **11j**)

The reaction mixture from step 1 was evaporated on a rotary evaporator and dried under high vacuum for 10 min. The residual material was dissolved in dry DMSO (1 mL) and NaSMe (29.7 mg, 2 equiv.) was added, and the mixture and stirred at 50 °C for 2 h. The reaction mixture was then diluted with EtOAc (25 mL), washed with deionized water (3 x 50 mL), and brine (15 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. The crude material was purified on a neutralized silica gel column by sequential elution with 10% EtOAc in hexanes, 15% EtOAc in hexanes, 20% EtOAc in hexanes, and 50% EtOAc in hexanes to give: **18** (6.5 mg, 5%) as an off-white solid, **11j** (52.4 mg, 49%) as a colorless, viscous oil, and **17** (15.4 mg, 12%) as an off-white solid.

3',5'-Di-*O*-(*t*-butyldimethylsilyl)-S⁴-methyl-4-thiothymidine (**11j**)


R_f (SiO₂/50% EtOAc in hexanes) = 0.67. ¹H NMR (500 MHz, CDCl₃): δ 7.67 (s, 1H, H-6), 6.27 (t, J = 6.3 Hz, 1H, H-1'), 4.36 (dt, J = 3.6, 6.4 Hz, 1H, H-3'), 3.96 (app q, J_{app} ~ 3.0 Hz, 1H, H-4'),



3.91 (dd, $J = 2.6, 11.4$ Hz, 1H, H-5'), 3.77 (dd, $J = 2.5, 11.4$ Hz, 1H, H-5'), 2.56 (s, 3H, SMe), 2.51 (ddd, $J = 4.0, 6.2, 13.4$ Hz, 1H, H-2'), 2.04-1.99 (m, 4H, H-2', Me), 0.91 and 0.89 (2s, 18H, *t*-Bu), 0.11 and 0.10 (2s, 6H, SiMe), 0.07 and 0.06 (2s, 6H, SiMe). ^{13}C NMR (125 MHz, CDCl_3): δ

178.4, 154.0, 136.9, 111.7, 88.2, 86.8, 71.6, 62.7, 42.5, 26.1, 26.0, 18.6, 18.2, 14.5, 13.3, -4.3, -4.7, -5.2. HRMS (ESI/TOF) m/z calculated for $\text{C}_{23}\text{H}_{45}\text{N}_2\text{O}_4\text{SSi}_2$ $[\text{M} + \text{H}]^+$: 501.2633, found 501.2631.


1-(3,5-Di-*O*-(*t*-butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-5-methyl-4-(3-oxido-1H-benzotriazol-1-yl)-2(1H)-pyrimidinone (17)



R_f (SiO_2 /50% EtOAc in hexanes) = 0.32. ^1H NMR (500 MHz, CDCl_3): δ 8.88 (d, $J = 8.6$ Hz, 1H, Ar-H), 8.19 (s, 1H, H-6), 8.02 (d, $J = 8.4$ Hz, 1H, Ar-H), 7.75 (t, $J = 7.8$ Hz, 1H, Ar-H), 7.55 (t, $J = 7.7$ Hz, 1H, Ar-H), 6.30 (t, $J = 6.3$ Hz, 1H, H-1'), 4.40 (dt, $J = 3.1, 6.1$ Hz, 1H, H-3'), 4.07 (app q, $J_{app} \sim 2.8$ Hz, 1H, H-4'), 3.95 (dd, $J = 2.5, 11.5$ Hz, 1H, H-5'), 3.80 (dd, $J =$

2.4, 11.5 Hz, 1H, H-5'), 2.64 (ddd, $J = 3.6, 6.1, 13.5$ Hz, 1H, H-2'), 2.50 (s, 3H, Me), 2.09 (dt, $J = 6.5, 13.3$ Hz, 1H, H-2'), 0.91 and 0.90 (2s, 18H, *t*-Bu), 0.12 and 0.11 (2s, 6H, SiMe), 0.09 and 0.08 (2s, 6H, SiMe). ^{13}C NMR (125 MHz, CDCl_3): δ 158.5, 154.0, 146.0, 133.9, 132.5, 131.9, 126.8, 118.6, 115.3, 105.3, 89.0, 87.9, 72.0, 62.9, 42.8, 26.1, 25.9, 18.6, 18.4, 18.2, -4.3, -4.7, -5.2. HRMS (ESI/TOF) m/z calculated for $\text{C}_{28}\text{H}_{46}\text{N}_5\text{O}_5\text{Si}_2$ $[\text{M} + \text{H}]^+$: 588.3032, found 588.3032.

4-(1H-Benzotriazol-1-yl)-1-(3,5-di-*O*-(*t*-butyldimethylsilyl)-2-deoxy-β-D-ribofuranosyl)-5-methyl-2(1H)-pyrimidinone (18)



R_f (SiO₂/20% EtOAc in hexanes) = 0.50. ¹H NMR (500 MHz, CDCl₃): δ 8.16 (s, 1H, H-6), 8.07 (d, J = 8.4 Hz, 1H, Ar-H), 7.52 (t, J = 7.5 Hz, 1H, Ar-H), 7.44–7.40 (m, 2H, Ar-H), 6.19 (t, J = 6.2 Hz, 1H, H-1'), 4.38 (dt, J = 3.4, 6.3 Hz, 1H, H-3'), 4.00 (app q, J_{app} ~ 2.9 Hz, 1H, H-4'), 3.96 (dd, J = 2.2, 11.5 Hz, 1H, H-5'), 3.80 (dd, J = 2.0, 11.5 Hz, 1H, H-5'), 2.51 (ddd, J = 4.1, 6.0, 13.4 Hz, 1H, H-2'), 2.28 (s, 3H, Me), 2.02 (dt, J = 6.4, 13.2 Hz, 1H, H-2'), 0.96 and 0.88 (2s, 18H, *t*-Bu), 0.16 and 0.14 (2s, 6H, SiMe), 0.07 (s, 6H, SiMe). ¹³C NMR (125 MHz, CDCl₃): δ 169.1, 154.0, 144.1, 143.8, 129.1, 128.9, 125.0, 120.8, 108.9, 100.7, 88.6, 87.6, 71.6, 62.7, 42.7, 26.2, 26.0, 18.7, 18.2, 12.2, -4.3, -4.7, -5.1. HRMS (ESI/TOF) m/z calculated for C₂₈H₄₆N₅O₅Si₂ [M + H]⁺: 588.3032, found 588.3018.

One-step procedure for aliphatic amines (synthesis of 6, 11a–f, 12a–d, 13a–d)

To a 0.424 M solution of the nucleoside derivative (**2**: 0.212 mmol, **7**: 0.219 mmol, **8**: 0.262 mmol) in THF, BOP (2 equiv.) and DBU (2 equiv.) were added, and the mixture was stirred at room temperature for 5 min. Then an *appropriate amine* (4 equiv.) was added to the mixture and the stirring was continued at room temperature until the consumption of the starting material was observed. The mixture was then diluted with EtOAc (25 mL), washed with deionized water (3 x 50 mL), and brine (15 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. The crude material was purified by chromatography on a silica gel column using a suitable eluting solvent (see individual compound headings above).

3',5'-Di-*O*-(*t*-butyldimethylsilyl)-*N*,5-dimethyl-2'-deoxycytidine (11a)

Chromatography on a silica gel column by sequential elution with EtOAc and 1% MeOH in EtOAc gave compound **11a** (92.6 mg, 90%) as a white solid, and the starting material **2** (7 mg, 7%).

*One-step procedure for reaction with p-toluidine (synthesis of **11g** and **12e**)*

To a solution of the nucleoside derivative (**2**: 0.212 mmol, **7**: 0.219 mmol) in dry CH₃CN (2 mL), BOP (2 equiv.) and DBU (4 equiv.) were added, and the mixture was stirred at room temperature for 5 min. Then *p*-toluidine (2 equiv.) was added and the mixture was stirred at 50 °C for 16 h. The mixture was then diluted with EtOAc (25 mL), washed with deionized water (3 x 50 mL), and brine (15 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. The crude material was purified by chromatography on a silica gel column using a suitable eluting solvent (see individual compound headings above).


*One-step procedure for reactions with thiols (synthesis of **11i-j**)*

To a solution of nucleoside derivative **2** (100 mg, 0.212 mmol, 1 equiv.) in dry DME (2 mL), BOP (188 mg, 0.425 mmol, 2 mol equiv) and DBU (127 µL, 0.850 mmol, 4 mol equiv) were added, and the mixture was stirred at room temperature for 5 min. Then an *appropriate thiol* (0.425 mmol, 2 equiv.) was added to the mixture and the stirring was continued at room temperature for 3 h. The reaction mixture was then diluted with EtOAc (25 mL), washed with deionized water (3 x 50 mL), and brine (15 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. The crude material was purified by chromatography on a neutralized silica gel column using a suitable eluting solvent (see individual compound headings above).

*Procedure for reactions with methyl and cyclohexyl alcohols (synthesis of **14a**, **14b**, and **15**)*

The reaction mixture from step 1 was evaporated on a rotary evaporator and dried under high vacuum for 10 min. The residual material was dissolved in the appropriate alcohol (20 equiv.) and DBU (2 equiv.) was added, and the mixture was stirred at room temperature until consumption of the corresponding benzotriazolyl ether intermediate was observed. The reaction mixture was then diluted with EtOAc (25 mL), washed with deionized water (3 x 50 mL), and brine (15 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered, and evaporated under reduced pressure. The crude material was purified by chromatography on a silica gel column using a suitable eluting solvent (see individual compound headings below).


3',5'-Di-*O*-(*t*-butyldimethylsilyl)-*O*⁴-methylthymidine (14a**)**



Chromatography on a silica gel column by sequential elution with 20% EtOAc in hexanes and 40% EtOAc in hexanes gave compound **14a** (93.4 mg, 91%) as a white solid. *R_f* (SiO₂/50% EtOAc in hexanes) = 0.56. ¹H NMR (500 MHz, CDCl₃): δ 7.68 (s, 1H, H-6), 6.28 (t, *J* = 6.4

Hz, 1H, H-1'), 4.32 (dt, *J* = 3.3, 6.3 Hz, 1H, H-3'), 3.91 (s, 3H, OMe), 3.88 (app q, *J_{app}* ~ 2.8 Hz, 1H, H-4'), 3.84 (dd, *J* = 2.5, 11.4 Hz, 1H, H-5'), 3.71 (dd, *J* = 2.3, 11.3 Hz, 1H, H-5'), 2.39 (ddd, *J* = 3.7, 6.1, 13.3 Hz, 1H, H-2'), 1.94 (dt, *J* = 6.6, 13.3 Hz, 1H, H-2'), 1.87 (s, 3H, Me), 0.86 and 0.82 (2s, 18H, *t*-Bu), 0.05 and 0.04 (2s, 6H, SiMe), 0.01 and 0.00 (2s, 6H, SiMe). ¹³C NMR (125 MHz, CDCl₃): δ 170.6, 155.9, 139.4, 104.2, 87.9, 86.3, 71.7, 62.6, 54.5, 42.2, 25.9, 25.8, 18.4, 18.0, 12.3, -4.6, -4.9, -5.3, -5.4. HRMS (ESI/TOF) *m/z* calculated for C₂₃H₄₅N₂O₅Si₂ [M + H]⁺: 485.2862, found 485.2863.

3',5'-Di-*O*-(*t*-butyldimethylsilyl)-*O*⁴-(cyclohex-1-yl)thymidine (14b**)**



Chromatography on a silica gel column by elution with 20% EtOAc in hexanes gave compound **14b** (80.0 mg, 88%) as a colorless liquid. R_f

(SiO_2 /20% EtOAc in hexanes) = 0.30. ^1H NMR (500 MHz, CDCl_3): δ

7.69 (s, 1H, H-6), 6.38 (t, $J = 6.4$ Hz, 1H, H-1'), 5.35–5.28 (m, 1H, OCH),

4.37 (dt, $J = 3.3, 6.5$ Hz, 1H, H-3'), 3.93 (app q, $J_{\text{app}} \sim 2.9$ Hz, 1H, H-4'), 3.89 (dd, $J = 2.6, 11.3$

Hz, H-5'), 3.76 (dd, $J = 2.4, 11.3$ Hz, H-5'), 2.44 (ddd, $J = 3.7, 6.2, 13.3$ Hz, 1H, H-2'), 1.99 (dt, J

= 6.6, 13.3 Hz, 1H, H-2'), 1.96–1.86 (m, 5H, Me, and cyclohexyl-H), 1.77–1.67 (m, 2H,

cyclohexyl-H), 1.58–1.48 (m, 2H, cyclohexyl-H), 1.47–1.38 (m, 2H, cyclohexyl-H), 1.36–1.23


(m, 2H, cyclohexyl-H), 0.92 and 0.88 (2s, 18H, *t*-Bu), 0.11 and 0.09 (2s, 6H, SiMe), 0.06 and

0.05 (2s, 6H, SiMe). ^{13}C NMR (125 MHz, CDCl_3): δ 170.0, 156.4, 139.3, 105.1, 87.9, 86.3, 74.4,

71.7, 62.8, 42.4, 31.6, 26.1, 26.0, 25.7, 23.7, 18.6, 18.2, 12.7, -4.4, -4.7, -5.1, -5.2. HRMS

(ESI/TOF) m/z calculated for $\text{C}_{28}\text{H}_{52}\text{N}_2\text{O}_5\text{Si}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$: 575.3307, found 575.3309.

3',5'-Di-*O*-(*t*-butyldimethylsilyl)-*O*⁴-methyl-2'-deoxyuridine (**15**)



Chromatography on a silica gel column by sequential elution with

20% EtOAc in hexanes and 40% EtOAc in hexanes gave compound **15**

(88.0 mg, 85%) as a colorless, viscous liquid. R_f (SiO_2 /50% EtOAc in

hexanes) = 0.59. ^1H NMR (500 MHz, CDCl_3): δ 8.19 (d, $J = 7.4$ Hz, 1H,

H-6), 6.24 (dd, $J = 4.8, 6.4$ Hz, 1H, H-1'), 5.81 (d, $J = 7.4$ Hz, 1H, H-5), 4.35 (app q, $J_{\text{app}} \sim 5.7$

Hz, 1H, H-3'), 3.94–3.91 (m, 4H, H-5', OMe), 3.89 (dt, $J = 2.3, 4.8$ Hz, 1H, H-4'), 3.75 (dd, $J =$

1.9, 11.4 Hz, 1H, H-5'), 2.45 (dt, $J = 6.5, 13.2$ Hz, 1H, H-2'), 2.09 (ddd, $J = 4.8, 6.4, 13.4$ Hz, 1H,

H-2'), 0.89 (s, 9H, *t*-Bu), 0.85 (s, 9H, *t*-Bu), 0.08 and 0.07 (2s, 6H, SiMe), 0.03 and 0.02 (2s,


6H, SiMe). ^{13}C NMR (125 MHz, CDCl_3): δ 171.8, 156.0, 143.0, 95.2, 87.6, 86.6, 70.0, 61.9,

54.5, 42.4, 26.0, 25.9, 18.5, 18.1, -4.4, -4.8, -5.3, -5.4. HRMS (ESI/TOF) m/z calculated for $C_{22}H_{42}N_2O_5Si_2Na$ $[M + Na]^+$: 493.2524, found 493.2524.

*Procedure for reactions with allyl and benzyl alcohols (synthesis of **16a** and **16b**)*


To the reaction mixture from step 1, the appropriate alcohol (0.525 mmol, 2 equiv.), and DBU (0.525 mmol, 2 mol equiv) were added, and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was then diluted with EtOAc (25 mL), washed with deionized water (3 x 50 mL), and brine (15 mL). The organic layer was dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The crude material was purified by chromatography on a silica gel column using a suitable eluting solvent (see individual compound headings below).

***O*⁴-Allyl-3'-azido-5'-*O*-*t*-butyldimethylsilyl-2',3'-dideoxythymidine (**16a**)**



Chromatography on a silica gel column eluted with 30% EtOAc in hexanes gave compound **16a** (61.6 mg, 56%) as a colorless liquid. R_f (SiO_2 /20% EtOAc in hexanes) = 0.30. 1H NMR (500 MHz, $CDCl_3$): δ 7.73 (s, 1H, H-6), 6.21 (t, J = 6.0 Hz, 1H, H-1'), 6.04 (ddt, J = 5.7, 11.0, 16.9 Hz, 1H, =CH), 5.38 (dd, J = 1.0, 17.2 Hz, 1H, =CH_{trans}), 5.26 (dd, J = 0.7, 10.5 Hz, 1H, =CH_{cis}), 4.89 (d, J = 5.4 Hz, 2H, OCH₂), 4.43 (app q, J = 5.9 Hz, 1H, H-3'), 4.00–3.96 (m, 2H, H-4' and H-5'), 3.81 (dd, J = 2.7, 11.7 Hz, 1H, H-5'), 2.62 (dt, J = 5.9, 13.7 Hz, 1H, H-2'), 2.24 (dt, J = 6.7, 13.5 Hz, 1H, H-2'), 1.96 (s, 3H, Me), 0.92 (s, 9H, *t*-Bu), 0.12 and 0.11 (2s, 6H, SiMe). ^{13}C NMR (125 MHz, $CDCl_3$): δ 170.2, 155.8, 139.4, 132.3, 118.3, 104.5, 86.3, 84.9, 67.9, 62.7, 60.0, 39.0, 26.0, 18.5, 12.5, -5.2, -5.3. HRMS (ESI/TOF) m/z calculated for $C_{19}H_{31}N_5O_4SiNa$ $[M + Na]^+$: 444.2038, found 444.2038.

3'-Azido- *O*⁴-benzyl-5'-*O*-*t*-butyldimethylsilyl-2',3'-dideoxythymidine (**16b**)




Chromatography on a silica gel column eluted with 30% EtOAc in hexanes gave compound **16b** (105.0 mg, 85%) as a colorless liquid.

R_f (SiO₂/40% EtOAc in hexanes) = 0.30. ¹H NMR (500 MHz, CDCl₃): δ 7.76 (s, 1H, H-6), 7.42 (d, J = 6.9 Hz, 2H, Ar-H), 7.38 (t, J =

7.2 Hz, 2H, Ar-H), 7.33 (t, J = 7.1 Hz, 1H, Ar-H), 6.23 (t, J = 6.0 Hz, 1H, H-1'), 5.44 (ABq, ΔY_{AB} = 11.9 Hz, J_{AB} = 12.7 Hz, 2H, OCH₂), 4.20–4.17 (m, 1H, H-3'), 4.01–3.96 (m, 2H, H-4' and H-5'), 3.81 (dd, J = 2.9, 12.2 Hz, 1H, H-5'), 2.63 (dt, J = 5.8, 13.7 Hz, 1H, H-2'), 2.25 (ddd, J = 6.2, 7.1, 13.5 Hz, 1H, H-2'), 1.97 (s, 3H, Me), 0.92 (s, 9H, *t*-Bu), 0.13 and 0.12 (2s, 6H, SiMe). ¹³C NMR (125 MHz, CDCl₃): δ 170.4, 155.9, 139.5, 136.1, 128.7, 128.4, 128.2, 104.6, 86.3, 85.0, 69.0, 62.7, 60.0, 39.1, 26.1, 18.6, 12.6, -5.1, -5.2. HRMS (ESI/TOF) m/z calculated for C₂₃H₃₃N₅O₄SiNa [M + Na]⁺: 494.2194, found 494.2194.

Undesired 3',5'-di-*O*-(*t*-butyldimethylsilyl)-*O*⁴-ethylthymidine (**19**) obtained in a reaction with NaSMe



To a solution of the nucleoside derivative **2** (100 mg, 0.212 mmol, 1 equiv.) in THF (0.5 mL), BOP (187.5 mg, 0.424 mmol, 2 mol equiv) and DBU (64 μ L, 0.424 mmol, 2 mol equiv) were added, and the mixture was stirred at room temperature for 30 min. The mixture was

evaporated on a rotary evaporator and dried under high vacuum for 10 min. The residual material was then dissolved in dry EtOH (1 mL), NaSMe (59.4 mg, 0.848 mmol, 4 equiv.) was added, and the mixture was stirred at room temperature for 12 h. The mixture was evaporated and the crude material was loaded onto a silica gel column. Sequential elution with 15% hexanes in EtOAc and 30% hexanes in EtOAc gave compound **19** (77.5 mg, 73%)

as a colorless, viscous liquid. R_f (SiO₂/50% EtOAc in hexanes) = 0.68. ¹H NMR (500 MHz, CDCl₃): δ 7.69 (s, 1H, H-6), 6.32 (t, J = 6.4 Hz, 1H, H-1'), 4.42 (t, J = 7.1 Hz, 2H, OCH₂), 4.35 (dt, J = 3.3, 6.3 Hz, 1H, H-3'), 3.91 (app q, J_{app} ~ 2.8 Hz, 1H, H-4'), 3.88 (dd, J = 2.6, 11.3 Hz, 1H, H-5'), 3.74 (dd, J = 2.5, 11.3 Hz, 1H, H-5'), 2.42 (ddd, J = 3.7, 6.1, 13.3 Hz, 1H, H-2'), 1.97 (dt, J = 6.6, 13.3 Hz, 1H, H-2'), 1.90 (s, 3H, Me), 1.33 (q, J = 7.1 Hz, 3H, Me), 0.89 and 0.86 (2s, 18H, *t*-Bu), 0.09 and 0.08 (2s, 6H, SiMe), 0.04 and 0.03 (2s, 6H, SiMe). ¹³C NMR (125 MHz, CDCl₃): δ 170.5, 156.1, 139.4, 104.5, 88.0, 86.4, 71.8, 63.3, 62.8, 42.4, 26.0, 25.9, 18.5, 18.2, 14.4, 12.5, -4.4, -4.7, -5.2. HRMS (ESI/TOF) m/z calculated for C₂₄H₄₆N₂O₅Si₂Na [M + Na]⁺: 521.2837, found 521.2858.

General procedure for the evaluation of various products formed with BOP from two commercial suppliers

To a solution of **2** (100.0 mg, 0.212 mmol, 1 equiv.) in dry THF (0.5 mL), BOP (188.0 mg, 0.424 mmol, 2 equiv.) and DBU were added, and the mixture was stirred at room temperature for a certain period of time.

Table 4: reactions with BOP from supplier 1 (Chem-Impex)


Conditions 1. DBU (64 μ L, 0.424 mmol, 2 equiv.) was used. The reaction mixture was stirred for 0.5 h and then evaporated. Chromatography through a plug of neutralized silica gel by initial elution with 15% EtOAc in hexanes gave compound **18** (1.0 mg, 1%) as a white solid. Subsequent elution with 25% EtOAc in hexanes gave a mixture of compounds **4** (39.1 mg, 31%) and **2** (14.1 mg, 14%) as a white, sticky solid. Further elution with 50% EtOAc in hexanes gave compound **17** (21.9 mg, 18%) as a white solid. Yields of **4** and **2** were calculated on the basis of the integration in the ¹H NMR spectrum of the mixture.

Conditions 2. DBU (64 μ L, 0.424 mmol, 2 equiv.) was used. The reaction mixture was stirred for 24 h and then evaporated. Chromatography through a plug of neutralized silica gel by initial elution with 30% EtOAc in hexanes gave a mixture of compounds **18** (12.0 mg, 10%) and **4** (39.1 mg, 31%) as a white solid. Subsequent elution with 50% EtOAc in hexanes gave compound **17** (39.4 mg, 32%) as a white solid. Yields of **18** and **4** were calculated on the basis of the integration in the ^1H NMR spectrum of the mixture.

Table 4: reactions with BOP from supplier 2 (Sigma-Aldrich)

Conditions 1. DBU (64 μ L, 0.424 mmol, 2 equiv.) was used. The reaction mixture was stirred for 0.5 h and then evaporated. Chromatography through a plug of neutralized silica gel by initial elution with 30% EtOAc in hexanes gave compound **4** (73.0 mg, 59%) as a white solid. Subsequent elution with 50% EtOAc in hexanes gave compound **17** (29.3 mg, 23%) as a white solid.

***O*⁴-(1*H*-Benzotriazol-1-yl)-3',5'-di-*O*-(*t*-butyldimethylsilyl)thymidine (**4**)**



R_f (SiO₂/20% EtOAc in hexanes) = 0.50. ^1H NMR (500 MHz, CDCl₃): δ 8.16 (s, 1H, H-6), 8.07 (d, J = 8.4 Hz, 1H, Ar-H), 7.52 (t, J = 7.5 Hz, 1H, Ar-H), 7.44–7.40 (m, 2H, Ar-H), 6.19 (t, J = 6.2 Hz, 1H, H-1'), 4.38 (dt, J = 3.4, 6.3 Hz, 1H, H-3'), 4.00 (app q, J_{app} \sim 2.9 Hz, 1H, H-4'), 3.96 (dd, J = 2.2, 11.5 Hz, 1H, H-5'), 3.80 (dd, J = 2.0, 11.5 Hz, 1H, H-5'), 2.51 (ddd, J = 4.1, 6.0, 13.4 Hz, 1H, H-2'), 2.28 (s, 3H, Me), 2.02 (dt, J = 6.4, 13.2 Hz, 1H, H-2'), 0.96 and 0.88 (2s, 18H, *t*-Bu), 0.16 and 0.14 (2s, 6H, SiMe), 0.07 (s, 6H, SiMe). ^{13}C NMR (125 MHz, CDCl₃): δ 169.1, 154.0, 144.1, 143.8, 129.1, 128.9, 125.0, 120.8, 108.9, 100.7, 88.6,

87.6, 71.6, 62.7, 42.7, 26.2, 26.0, 18.7, 18.2, 12.2, -4.3, -4.7, -5.1. HRMS (ESI/TOF) m/z calculated for $C_{28}H_{46}N_5O_5Si_2$ $[M + H]^+$: 588.3032, found 588.3018.

Conditions 2. DBU (64 μ L, 0.424 mmol, 2 equiv.) was used. The reaction mixture was stirred for 24 h and then evaporated. Chromatography through a plug of neutralized silica gel by initial elution with 30% EtOAc in hexanes gave a mixture of compounds **18** (4.2 mg, 3%) and **4** (27.0 mg, 22%) as a white solid. Subsequent elution with 50% EtOAc in hexanes gave compound **17** (57.4 mg, 46%) as a white solid. Yields of **18** and **4** were calculated on the basis of the integration in 1H NMR spectrum of the mixture.

Conditions 3. DBU (127 μ L, 0.424 mmol, 4 equiv.) was used. The reaction was stirred for 24 h and then evaporated. Chromatography through a plug of neutralized silica gel by initial elution with 30% EtOAc in hexanes gave a mixture of compounds **18** (31.4 mg, 26%) as a white solid. Subsequent elution with 50% EtOAc in hexanes gave compound **17** (10.5 mg, 8%) as a white solid.

Procedure for the deoxygenation of 17 to 18 with $B_2(OH)_4$


To a solution of *N*-oxide **17** (20 mg, 0.034 mmol, 1 mol equiv) in dry MeCN (0.2 mL) $B_2(OH)_4$ (3.7 mg, 0.041 mmol, 1.2 equiv.) was added, and the mixture was stirred at 60 °C for 2 h. The mixture was then evaporated and the crude material was purified on a silica gel column eluted with 30% EtOAc in hexanes to give compound **18** (18.8 mg, 97%) as a white solid.

Procedure for desilylation reactions

Method A (with *n*- Bu_4NF /THF for synthesis of **5**, **20b-i**, **21a-d**, **22a-d**, **23b**, **25a-b**)


To a 0.115 M solution of the appropriate nucleoside (1 equiv.) in dry THF, *n*-Bu₄NF (1 M solution in THF, 2.4 equiv.) was added, and the mixture was stirred at room temperature for 20 min. The mixture was evaporated and the crude material was purified by chromatography on a short silica gel column using a suitable eluting solvent (see individual compound headings below)

1-(2-Deoxy-β-D-ribofuranosyl)-5-methyl-4-(morpholin-4-yl)-2(1*H*)-pyrimidinone (5)



Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **5** (83.4 mg, 96%) as a white solid. *R_f* (SiO₂/10% MeOH in EtOAc) = 0.18. ¹H NMR (500 MHz, CD₃OD): δ 7.98 (s, 1H, H-6), 6.26 (t, *J* = 6.4 Hz, 1H, H-1'), 4.41 (dt, *J* = 3.7, 6.4 Hz, 1H, H-3'), 3.96 (app q, *J_{app}* ~ 3.5 Hz, 1H, H-4'), 3.85 (dd, *J* = 3.1, 12.1 Hz, 1H, H-5'), 3.78–3.75 (m, 5H, morpholinyl-CH₂ and H-5'), 3.72–3.70 (m, 4H, morpholinyl-CH₂), 2.39 (ddd, *J* = 4.0, 6.1, 13.5 Hz, 1H, H-2'), 2.21–2.14 (m, 4H, Me and H-2'). ¹³C NMR (125 MHz, CD₃OD): δ 167.4, 157.5, 143.6, 105.8, 88.9, 87.6, 71.8, 67.8, 62.6, 48.8, 42.1, 17.9. HRMS (ESI/TOF) *m/z* calculated for C₁₄H₂₁N₃O₅Na [M + Na]⁺: 334.1373, found 334.1366.


N-Benzyl-5-methyl-2'-deoxycytidine (20b)



Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **20b** (54.2 mg, 92%) as a white solid. *R_f* (SiO₂/10% MeOH in EtOAc) = 0.24. ¹H NMR (500 MHz, CD₃OD): δ 7.82 (s, 1H, H-6), 7.35 (d, *J* = 7.1 Hz, 2H, Ar-H), 7.31 (t, *J* = 7.5 Hz, 2H, Ar-H), 7.23 (t, *J* = 7.2 Hz, 1H, Ar-H), 6.30 (t, *J* = 6.5 Hz, 1H, H-1'), 4.71 (s, 2H, CH₂), 4.40 (dt, *J* = 3.3, 6.4 Hz, 1H, H-3'), 3.94 (app q, *J_{app}* ~ 3.4 Hz, 1H, H-4'), 3.84 (dd, *J* = 3.1, 12.1 Hz, 1H, H-5'), 3.76 (dd, *J* = 3.8, 12.1 Hz, 1H, H-5'), 2.34 (ddd, *J* = 3.8, 5.9, 13.5 Hz, 1H, H-2'), 2.17 (dt, *J* = 6.7,


13.5 Hz, 1H, H-2'), 2.00 (s, 3H, Me). ^{13}C NMR (125 MHz, CD_3OD): δ 164.9, 158.6, 140.3, 138.9, 129.3, 128.6, 128.0, 104.9, 88.7, 87.3, 72.0, 62.8, 45.1, 41.9, 13.2. HRMS (ESI/TOF) m/z calculated for $\text{C}_{17}\text{H}_{21}\text{N}_3\text{O}_4\text{Na}$ $[\text{M} + \text{Na}]^+$: 354.1424, found 354.1440.

***N,N*,5-Trimethyl-2'-deoxycytidine (20c)**



Chromatography on a silica gel column by sequential elution with EtOAc and 20% MeOH in EtOAc gave compound **20c** (51.5 mg, 96%) as an off-white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.10. ^1H NMR (500 MHz, CD_3OD): δ 7.81 (s, 1H, H-6), 6.23 (t, J = 6.5 Hz, 1H, H-1'), 4.38 (dt, J = 3.4, 6.5 Hz, 1H, H-3'), 3.92 (app q, J_{app} \sim 3.5 Hz, 1H, H-4'), 3.81 (dd, J = 3.2, 12.0 Hz, 1H, H-5'), 3.73 (dd, J = 3.7, 12.0 Hz, 1H, H-5'), 3.21 (s, 6H, NMe_2), 2.32 (ddd, J = 3.8, 6.1, 13.5 Hz, 1H, H-2'), 2.25 (s, 3H, Me), 2.15 (dt, J = 6.7, 13.5 Hz, 1H, H-2'). ^{13}C NMR (125 MHz, CD_3OD): δ 166.9, 157.4, 142.3, 105.2, 88.8, 87.3, 71.9, 62.7, 41.9, 40.6, 18.7. HRMS (ESI/TOF) m/z calculated for $\text{C}_{12}\text{H}_{19}\text{N}_3\text{O}_4\text{Na}$ $[\text{M} + \text{Na}]^+$: 292.1268, found 292.1272.


***N,N*-Diethyl-5-methyl-2'-deoxycytidine (20d)**



Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **20d** (81.1 mg, 96%) as a white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.20. ^1H NMR (500 MHz, CD_3OD): δ 7.83 (s, 1H, H-6), 6.26 (t, J = 6.5 Hz, 1H, H-1'), 4.41 (dt, J = 3.4, 6.5 Hz, 1H, H-3'), 3.95 (app q, J_{app} \sim 3.5 Hz, 1H, H-4'), 3.84 (dd, J = 3.1, 12.0 Hz, 1H, H-5'), 3.76 (dd, J = 3.7, 12.0 Hz, 1H, H-5'), 3.66 (q, J = 7.0 Hz, 4H, NCH_2), 2.35 (ddd, J = 3.8, 6.1, 13.5 Hz, 1H, H-2'), 2.25 (s, 3H, Me), 2.19 (dt, J = 6.7, 13.5 Hz, 1H, H-2'), 1.26 (t, J = 7.0 Hz, 6H, Me). ^{13}C NMR (125 MHz, CD_3OD): δ 165.1, 157.4, 142.6, 104.8, 88.8, 87.3, 71.9, 62.7, 45.0,


41.9, 18.7, 14.1. HRMS (ESI/TOF) m/z calculated for $C_{14}H_{23}N_3O_4Na$ $[M + Na]^+$: 320.1581, found 320.1568.

1-(2-Deoxy- β -D-ribofuranosyl)-5-methyl-4-(pyrrolidin-1-yl)-2(1*H*)-pyrimidinone (20e)



Chromatography on a silica gel column by sequential elution with EtOAc and 20% MeOH in EtOAc gave compound **20e** (54.6 mg, 97%) as an off-white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.12. 1H NMR (500 MHz, CD_3OD): δ 7.75 (s, 1H, H-6), 6.24 (t, J = 6.6 Hz, 1H, H-1'), 4.38 (dt, J = 3.4, 6.5 Hz, 1H, H-3'), 3.91 (app q, J_{app} \sim 3.4 Hz, 1H, H-4'), 3.81 (dd, J = 3.1, 12.0 Hz, 1H, H-5'), 3.78-3.72 (m, 5H, H-5' and NCH_2), 2.30 (ddd, J = 3.8, 6.1, 13.5 Hz, 1H, H-2'), 2.25 (s, 3H, Me), 2.17-2.12 (m, 1H, H-2'), 1.93 (br s, 4H, $(CH_2)_2$). ^{13}C NMR (125 MHz, CD_3OD): δ 163.9, 157.6, 141.2, 105.2, 88.7, 87.2, 72.0, 62.8, 50.6, 41.9, 26.1, 18.1. HRMS (ESI/TOF) m/z calculated for $C_{14}H_{21}N_3O_4Na$ $[M + Na]^+$: 318.1424, found 318.1403.


1-(2-Deoxy- β -D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(1*H*)-pyrimidinone (20f)



Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc, gave compound **20f** (53.9 mg, 94%) as a white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.20. 1H NMR (500 MHz, CD_3OD): δ 7.90 (s, 1H, H-6), 6.26 (t, J = 6.5 Hz, 1H, H-1'), 4.41 (dt, J = 3.5, 6.6 Hz, 1H, H-3'), 3.95 (app q, J_{app} \sim 3.5 Hz, 1H, H-4'), 3.85 (dd, J = 3.2, 12.1 Hz, 1H, H-5'), 3.76 (dd, J = 3.7, 12.1 Hz, 1H, H-5'), 3.68-3.64 (m, 4H, NCH_2), 2.37 (ddd, J = 3.9, 6.1, 13.5 Hz, 1H, H-2'), 2.21-2.15 (m, 4H, Me and H-2'), 1.77-1.72 (m, 2H, CH_2), 1.71-1.66 (m, 4H, CH_2). ^{13}C NMR (125 MHz, CD_3OD): δ 167.2, 153.8, 143.1, 105.9, 88.9, 87.4, 71.9, 62.7, 49.4, 42.0, 27.3, 25.5,


18.2. HRMS (ESI/TOF) m/z calculated for $C_{15}H_{23}N_3O_4Na$ $[M + Na]^+$: 332.1581, found 332.1584.

5-Methyl-*N*-(*p*-tolyl)-2'-deoxycytidine (20g)



Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **20g** (83.2 mg, 94%) as an off-white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.30. 1H NMR (500 MHz, CD_3OD): δ 7.90 (s, 1H, H-6), 7.52 (d, J = 8.3 Hz, 2H, Ar-H), 7.12 (d, J = 8.2 Hz, 2H, Ar-H), 6.26 (t, J = 6.5 Hz, 1H, H-1'), 4.38 (dt, J = 3.4, 6.6 Hz, 1H, H-3'), 3.93 (app q, J_{app} ~ 3.5 Hz, 1H, H-4'), 3.83 (dd, J = 3.2, 12.1 Hz, 1H, H-5'), 3.74 (dd, J = 3.8, 12.1 Hz, 1H, H-5'), 2.34 (ddd, J = 3.9, 6.1, 13.5 Hz, 1H, H-2'), 2.30 (s, 3H, Me), 2.19 (dt, J = 6.7, 13.5 Hz, 1H, H-2'), 2.08 (s, 3H, Me). ^{13}C NMR (125 MHz, CD_3OD): δ 163.5, 158.3, 139.8, 136.9, 135.6, 130.0, 124.5, 105.5, 88.8, 87.5, 71.9, 62.7, 42.0, 21.0, 13.6. HRMS (ESI/TOF) m/z calculated for $C_{17}H_{22}N_3O_4$ $[M + H]^+$: 332.1605, found 332.1604.


S⁴-Ethyl-4-thiothymidine (20h)



Chromatography on a neutralized silica gel column by sequential elution with EtOAc and 5% MeOH in EtOAc gave compound **20h** (58.7 mg, 70%) as a white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.36. 1H NMR (500 MHz, CD_3OD): δ 8.09 (s, 1H, H-6), 6.20 (t, J = 6.2 Hz, 1H, H-1'), 4.38 (dt, J = 3.6, 6.6 Hz, 1H, H-3'), 3.98 (app q, J_{app} ~ 3.5 Hz, 1H, H-4'), 3.85 (dd, J = 2.9, 12.2 Hz, 1H, H-5'), 3.75 (dd, J = 3.6, 12.2 Hz, 1H, H-5'), 3.20 (q, J = 7.4 Hz, 2H, SCH_2), 2.46 (ddd, J = 4.5, 6.0, 13.6 Hz, 1H, H-2'), 2.16 (dt, J = 6.6, 13.4 Hz, 1H, H-2'), 2.04 (s, 3H, Me), 1.35 (t, J = 7.4 Hz, 3H, Me). ^{13}C NMR (125 MHz, CD_3OD): δ 179.9, 156.0, 139.4, 114.2, 89.3, 88.3, 71.5,


62.4, 42.4, 25.1, 14.5, 14.2. HRMS (ESI/TOF) m/z calculated for $C_{12}H_{18}N_2O_4SNa$ $[M + Na]^+$: 309.0879, found 309.0866.

S⁴-Benzyl-4-thiothymidine (**20i**)



Chromatography on neutralized silica gel column by sequential elution with EtOAc and 5% MeOH in EtOAc, gave compound **20i** (95.7 mg, 79%) as a white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.37. 1H NMR (500 MHz, CD_3OD): δ 8.13 (s, 1H, H-6), 7.42 (d, J = 7.9 Hz, 2H, Ar-H), 7.30 (t, J = 7.3 Hz, 2H, Ar-H), 7.24 (t, J = 7.1 Hz, 1H, Ar-H), 6.22 (t, J = 6.2 Hz, 1H, H-1'), 4.47 (s, 2H, SCH_2), 4.38 (dt, J = 4.0, 5.7 Hz, 1H, H-3'), 3.98 (app q, J_{app} ~ 3.5 Hz, 1H, H-4'), 3.85 (dd, J = 3.0, 12.2 Hz, 1H, H-5'), 3.75 (dd, J = 3.7, 12.2 Hz, 1H, H-5'), 2.48 (ddd, J = 4.4, 6.2, 13.6 Hz, 1H, H-2'), 2.18 (dt, J = 6.6, 13.4 Hz, 1H, H-2'), 2.04 (s, 3H, Me). ^{13}C NMR (125 MHz, CD_3OD): δ 179.1, 155.9, 139.8, 138.3, 130.3, 129.6, 128.4, 113.9, 89.2, 88.3, 71.5, 62.3, 42.4, 34.7, 14.1. HRMS (ESI/TOF) m/z calculated for $C_{17}H_{20}N_2O_4SNa$ $[M + Na]^+$: 371.1036, found 371.1035.


N-Benzyl-2'-deoxycytidine (**21a**)



Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **21a** (53.6 mg, 92%) as a white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.24. 1H NMR (500 MHz, CD_3OD): δ 7.91 (d, J = 7.5 Hz, 1H, H-6), 7.34–7.28 (m, 4H, Ar-H), 7.25–7.22 (m, 1H, Ar-H), 6.27 (t, J = 6.5 Hz, 1H, H-1'), 5.90 (d, J = 7.5 Hz, 1H, H-5), 4.59–4.56 (m, 2H, NCH_2), 4.36 (dt, J = 3.3, 6.4 Hz, 1H, H-3'), 3.93 (app q, J_{app} ~ 3.6 Hz, 1H, H-4'), 3.78 (dd, J = 3.3, 12.0 Hz, 1H, H-5'), 3.72 (dd, J = 3.9, 12.0 Hz, 1H, H-5'), 2.34 (ddd, J = 3.7, 6.1, 13.5 Hz, 1H, H-2'), 2.13 (dt, J = 6.7, 13.5 Hz, 1H, H-2'). ^{13}C NMR (125 MHz, CD_3OD): δ 165.4, 158.7,


141.3, 139.7, 129.5, 128.8, 128.3, 96.9, 88.8, 87.5, 72.1, 62.8, 45.2, 41.9. HRMS (ESI/TOF) m/z calculated for $C_{16}H_{19}N_3O_4Na$ $[M + Na]^+$: 340.1268, found 340.1265.

1-(2-Deoxy- β -D-ribofuranosyl)-4-(pyrrolidin-1-yl)-2(1H)-pyrimidinone (21b)



Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **21b** (72.1 mg, 87%) as a white solid. R_f (SiO_2 /20% MeOH in EtOAc) = 0.22. 1H NMR (500 MHz, CD_3OD): δ 8.01 (d, J = 7.6 Hz, 1H, H-6), 6.26 (t, J = 6.5 Hz, 1H, H-1'), 5.96 (d, J = 7.7 Hz, 1H, H-5), 4.36 (dt, J = 3.3, 6.4 Hz, 1H, H-3'), 3.93 (app q, J_{app} ~ 3.5 Hz, 1H, H-4'), 3.79 (dd, J = 3.2, 12.0 Hz, 1H, H-5'), 3.72 (dd, J = 3.8, 12.0 Hz, 1H, H-5'), 3.56 (t, J = 6.8 Hz, 2H, NCHH), 3.46 (t, J = 6.8 Hz, 2H, NCHH), 2.35 (ddd, J = 4.0, 5.9, 13.5 Hz, 1H, H-2'), 2.03 (dt, J = 6.6, 13.4 Hz, 1H, H-2'), 2.03 (quint, J = 6.7 Hz, 2H, CH_2), 1.95 (quint, J = 6.7 Hz, 2H, CH_2). ^{13}C NMR (125 MHz, CD_3OD): δ 162.8, 158.0, 142.0, 95.0, 88.8, 87.5, 72.0, 62.8, 48.2, 48.1, 42.1, 26.5, 25.7. HRMS (ESI/TOF) m/z calculated for $C_{13}H_{19}N_3O_4Na$ $[M + Na]^+$: 304.1268, found 304.1272.

1-(2-Deoxy- β -D-ribofuranosyl)-4-(piperidin-1-yl)-2(1H)-pyrimidinone (21c)




Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **21c** (52.1 mg, 90%) as a white solid. R_f (SiO_2 /20% MeOH in EtOAc) = 0.17. 1H NMR (500 MHz, CD_3OD): δ 8.00 (d, J = 7.9 Hz, 1H, H-6), 6.24 (t, J = 6.5 Hz, 1H, H-1'), 6.21 (d, J = 7.9 Hz, 1H, H-5), 4.36 (dt, J = 3.4, 6.5 Hz, 1H, H-3'), 3.93 (app q, J_{app} ~ 3.5 Hz, 1H, H-4'), 3.89–3.69 (m, 2H, NCHH), 3.79 (dd, J = 3.3, 12.0 Hz, 1H, H-5'), 3.72 (dd, J = 3.7, 12.1 Hz, 1H, H-5'), 3.67–3.55 (m, 2H, NCHH), 2.35 (ddd, J = 3.8, 6.1, 13.5 Hz, 1H, H-2'), 2.35 (dt, J = 6.7, 13.5 Hz, 1H, H-2'), 1.76–1.69 (m, 2H, CH_2), 1.65–1.57 (m, 4H, CH_2). ^{13}C NMR (125 MHz, CD_3OD): δ

163.8, 158.3 (br), 142.5, 93.6, 88.8, 87.5, 72.1, 62.8, 47.8 (br), 47.8 (br), 42.0, 27.0 (br), 25.5.

HRMS (ESI/TOF) m/z calculated for $C_{14}H_{21}N_3O_4Na$ $[M + Na]^+$: 318.1424, found 318.1449.


1-(2-Deoxy- β -D-ribofuranosyl)-4-(morpholin-4-yl)-2(1H)-pyrimidinone (21d)



Chromatography on a silica gel column by sequential elution with EtOAc followed by 15% MeOH in EtOAc gave compound **21d** (54.2 mg, 93%) as a white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.12. 1H NMR (500 MHz, CD_3OD): δ 8.08 (d, J = 7.8 Hz, 1H, H-6), 6.24 (t, J = 6.4 Hz, 1H, H-1'), 6.20 (d, J = 7.8 Hz, 1H, H-5), 4.36 (dt, J = 3.4, 6.4 Hz, 1H, H-3'), 3.94 (app q, J_{app} ~ 3.5

Hz, 1H, H-4'), 3.79 (dd, J = 3.3, 12.0 Hz, 1H, H-5'), 3.74–3.55 (m, 9H, H-5' and morpholinyl-CH₂), 2.37 (ddd, J = 3.9, 6.1, 13.5 Hz, 1H, H-2'), 2.14 (dt, J = 6.7, 13.4 Hz, 1H, H-2'). ^{13}C NMR (125 MHz, CD_3OD): δ 164.5, 158.1, 143.0, 93.3, 88.9, 87.7, 72.0, 67.5, 62.7, 46.6 (br), 45.1 (br), 42.1. HRMS (ESI/TOF) m/z calculated for $C_{13}H_{19}N_3O_5Na$ $[M + Na]^+$: 320.1217, found 320.1213.

3'-Azido-*N,N*-diethyl-5-methyl-2',3'-dideoxycytidine (22a)




Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **22a** (71.0 mg, 96%) as an off-white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.59. 1H NMR (500 MHz, CD_3OD): δ 7.80 (s, 1H, H-6), 6.13 (t, J = 6.2 Hz, 1H, H-1'), 4.32 (app q, J_{app} ~ 6.1 Hz, 1H, H-3'), 3.92 (dt, J = 3.2, 4.9 Hz, 1H, H-4'), 3.86 (dd, J = 3.1, 12.2

Hz, 1H, H-5'), 3.75 (dd, J = 3.2, 12.2 Hz, 1H, H-5'), 3.63 (q, J = 7.0 Hz, 4H, NCH₂), 2.44 (dt, J = 6.4, 13.2 Hz, 1H, H-2'), 2.36 (dt, J = 6.7, 13.5 Hz, 1H, H-2'), 2.22 (s, 3H, Me), 1.23 (t, J = 7.0 Hz, 6H, Me). ^{13}C NMR (125 MHz, CD_3OD): δ 165.2, 157.3, 142.5, 104.8, 87.0, 86.2, 62.3, 61.4,


45.0, 39.0, 18.7, 14.1. HRMS (ESI/TOF) m/z calculated for $C_{14}H_{22}N_6O_3Na$ $[M + Na]^+$: 345.1646, found 345.1646.

1-(3-Azido-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(pyrrolidin-1-yl)-2(1H)-pyrimidinone (22b)



Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **22b** (71.5 mg, 97%) as an off-white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.20. 1H NMR (500 MHz, CD_3OD): δ 7.75 (s, 1H, H-6), 6.13 (t, J = 6.2 Hz, 1H, H-1'), 4.32 (app q, J_{app} ~ 6.0 Hz, 1H, H-3'), 3.91 (app q, J_{app} ~ 3.9 Hz, 1H, H-4'), 3.85 (dd, J = 3.1, 12.2 Hz, 1H, H-5'), 3.76–3.66 (m, 5H, H-5' and NCH_2), 2.41 (dt, J = 6.3, 13.1 Hz, 1H, H-2'), 2.36 (dt, J = 6.7, 13.5 Hz, 1H, H-2'), 2.24 (s, 3H, Me), 1.92 (br s, 4H, CH_2). ^{13}C NMR (125 MHz, CD_3OD): δ 163.2, 157.4, 141.0, 105.2, 86.9, 86.1, 62.4, 61.5, 50.6 (br), 38.9, 26.2 (br), 18.1. HRMS (ESI/TOF) m/z calculated for $C_{14}H_{21}N_6O_3$ $[M + H]^+$: 321.1670, found 321.1663.


1-(3-Azido-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(1H)-pyrimidinone (22c)



Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **22c** (122.1 mg, 99%) as an off-white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.60. 1H NMR (500 MHz, CD_3OD): δ 7.87 (s, 1H, H-6), 6.13 (t, J = 6.1 Hz, 1H, H-1'), 4.32 (app q, J_{app} ~ 6.1 Hz, 1H, H-3'), 3.93 (dt, J = 2.8, 5.3 Hz, 1H, H-4'), 3.86 (dd, J = 3.0, 12.2 Hz, 1H, H-5'), 3.75 (dd, J = 3.2, 12.2 Hz, 1H, H-5'), 3.66–3.60 (m, 4H, NCH_2), 2.45 (dt, J = 6.4, 13.2 Hz, 1H, H-2'), 2.35 (dt, J = 6.7, 13.5 Hz, 1H, H-2'), 2.15 (s, 3H, Me), 1.75–1.68 (m, 2H, CH_2), 1.68–1.61 (m, 4H, CH_2). ^{13}C NMR (125 MHz, CD_3OD): δ 167.2, 157.5, 142.9, 105.9, 87.1, 86.3, 62.3, 61.3,

49.4, 39.1, 27.3, 25.5, 18.2. HRMS (ESI/TOF) m/z calculated for $C_{15}H_{22}N_6O_3Na$ $[M + Na]^+$: 357.1646, found 357.1670.


1-(3-Azido-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(morpholin-4-yl)-2(1H)-pyrimidinone (22d)



Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **22d** (73.2 mg, 98%) as a white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.23. 1H NMR (500 MHz, CD_3OD): δ 7.96 (s, 1H, H-6), 6.13 (t, J = 6.0 Hz, 1H, H-1'), 4.32 (app q, J_{app} ~ 6.2 Hz, 1H, H-3'), 3.94 (dt, J = 2.9, 5.4 Hz, 1H, H-4'), 3.87 (dd, J = 3.1, 12.2 Hz, 1H, H-5'),

3.77-3.73 (m, 5H, H-5', and morpholinyl- CH_2), 3.71-3.68 (m, 4H, morpholinyl- CH_2), 2.47 (dt, J = 6.5, 13.3 Hz, 1H, H-2'), 2.37 (dt, J = 6.6, 13.5 Hz, 1H, H-2'), 2.15 (s, 3H, Me). ^{13}C NMR (125 MHz, CD_3OD): δ 167.0, 156.9, 143.6, 105.8, 87.3, 86.4, 67.8, 62.1, 61.1, 48.9, 39.1, 17.9. HRMS (ESI/TOF) m/z calculated for $C_{14}H_{20}N_6O_4Na$ $[M + Na]^+$: 359.1438, found 359.1434.

O⁴-(Cyclohex-1-yl)thymidine (23b)




Chromatography on a silica gel column by sequential elution with 20% EtOAc in hexanes and EtOAc gave compound **23b** (33.1 mg, 89%) as a white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.58. 1H NMR (500 MHz, CD_3OD): δ 8.11 (d, J = 0.9 Hz, 1H, H-6), 6.24 (t, J = 6.4 Hz, 1H, H-1'), 5.18 (m, 1H, OCH), 4.38 (dt, J = 3.9, 6.3 Hz, 1H, H-3'), 3.95 (app q, J_{app} ~ 3.5 Hz,

1H, H-4'), 3.83 (dd, J = 3.1, 12.1 Hz, 1H, H-5'), 3.74 (dd, J = 3.7, 12.1 Hz, 1H, H-5'), 2.40 (ddd, J = 4.0, 6.1, 13.6 Hz, 1H, H-2'), 2.19-2.11 (m, 1H, H-2'), 2.00-1.91 (m, 2H, cyclohexyl-H), 1.96 (s, 3H, Me), 1.82-1.73 (m, 2H, cyclohexyl-H), 1.62-1.52 (m, 3H, cyclohexyl-H), 1.50-1.30 (m, 3H, cyclohexyl-H). ^{13}C NMR (125 MHz, CD_3OD): δ 171.6, 158.4, 141.9, 107.0, 89.1, 87.9,


76.3, 71.7, 62.5, 42.2, 32.4, 32.3, 26.5, 24.6, 12.2. HRMS (ESI/TOF) m/z calculated for $C_{16}H_{24}N_2O_5Na$ $[M + Na]^+$: 347.1577, found 347.1578.

***O*⁴-Allyl-3'-azido-2',3'-dideoxythymidine (25a)**



Chromatography on a silica gel column by sequential elution with 20% EtOAc in hexanes and EtOAc gave compound **25a** (45.0 mg, 90%) as a white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.77. 1H NMR (500 MHz, $CDCl_3$): δ 7.78 (s, 1H, H-6), 6.05–5.97 (m, 2H, H-1' and =CH), 5.36 (d, J = 17.2 Hz, 1H, =CH_{trans}), 5.25 (d, J = 10.5 Hz, 1H, =CH_{cis}), 4.86 (d, J = 5.5 Hz, 2H, OCH₂), 4.39 (app q, J_{app} ~ 5.7 Hz, 1H, H-3'), 4.03–3.95 (m, 2H, H-4' and H-5'), 3.83 (d, J = 11.1 Hz, 1H, H-5'), 3.72 (br s, 1H, OH), 2.56 (dt, J = 6.6, 13.4 Hz, 1H, H-2'), 2.46 (dt, J = 6.3, 13.2 Hz, 1H, H-2'), 1.95 (s, 3H, Me). ^{13}C NMR (125 MHz, $CDCl_3$): δ 170.4, 156.1, 141.3, 132.1, 118.5, 105.3, 88.4, 85.3, 68.0, 61.9, 59.9, 38.1, 12.4. HRMS (ESI/TOF) m/z calculated for $C_{13}H_{17}N_5O_4Na$ $[M + Na]^+$: 330.1173, found 330.1177.

***3'*-Azido-*O*⁴-benzyl-2',3'-dideoxythymidine (25b)**




Chromatography on a silica gel column by sequential elution with 20% EtOAc in hexanes and EtOAc gave compound **25b** (35.1 mg, 93%) as a white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.80. 1H NMR (500 MHz, $CDCl_3$): δ 7.76 (s, 1H, H-6), 7.40 (d, J = 6.9 Hz, 2H, Ar-H), 7.37 (t, J = 7.2 Hz, 2H, Ar-H), 7.34–7.31 (m, 1H, Ar-H), 6.05 (t, J = 5.9 Hz, 1H, H-1'), 5.41 (s, 2H, OCH₂), 4.40 (app q, J_{app} ~ 5.6 Hz, 1H, H-3'), 4.04–3.97 (m, 2H, H-4', and H-5'), 3.83 (d, J = 10.2 Hz, 1H, H-5'), 3.61–3.47 (br, 1H, OH), 2.60 (dt, J = 6.5, 13.2 Hz, 1H, H-2'), 2.47 (dt, J = 6.4, 13.2 Hz, 1H, H-2'), 1.96 (s, 3H, Me). ^{13}C NMR (125 MHz, $CDCl_3$): δ 170.6, 156.1, 141.4,

135.9, 128.7, 128.4, 128.2, 105.3, 88.3, 85.3, 69.0, 61.8, 59.9, 39.1, 12.4. HRMS (ESI/TOF) m/z calculated for $C_{17}H_{20}N_5O_4$ $[M + H]^+$: 358.1510, found 358.1510.

Method B (with KF for synthesis of **20a** and **21e**)

To a 0.096 M solution of the appropriate nucleoside (1 equiv.) in dry MeOH, KF (4 equiv.) was added, and the mixture was stirred at 80 °C for 12 h. The mixture was evaporated and the crude material was purified through a short silica gel column by elution with suitable solvent system (see individual compound headings below).


***N*,5-Dimethyl-2'-deoxycytidine (20a)**



Chromatography on a silica gel column by sequential elution with EtOAc and 20% MeOH in EtOAc gave compound **20a** (35.4 mg, 89%) as a white solid. R_f (SiO_2 /20% MeOH in EtOAc) = 0.16. 1H NMR (500 MHz, CD_3OD): δ 7.73 (s, 1H, H-6), 6.28 (t, J = 6.6 Hz, 1H, H-1'), 4.37 (dt, J = 3.4, 6.5 Hz, 1H, H-3'), 3.91 (app q, J_{app} ~ 3.5 Hz, 1H, H-4'), 3.80 (dd, J = 3.2, 12.0 Hz, 1H, H-5'), 3.73 (dd, J = 3.8, 12.1 Hz, 1H, H-5'), 2.94 (s, 3H, NMe), 2.30 (ddd, J = 3.7, 6.1, 13.5 Hz, 1H, H-2'), 2.13 (dt, J = 6.7, 13.5 Hz, 1H, H-2'), 1.93 (s, 3H, Me). ^{13}C NMR (125 MHz, CD_3OD): δ 165.4, 158.6, 138.3, 105.0, 88.7, 87.2, 72.0, 62.8, 41.9, 28.3, 13.1. HRMS (ESI/TOF) m/z calculated for $C_{11}H_{17}N_3O_4Na$ $[M + Na]^+$: 278.1111, found 278.1123.

***N*-(*p*-Tolyl)-2'-deoxycytidine (21e)**

Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **21e** (42.9 mg, 87%) as a white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.40. 1H NMR (500 MHz, CD_3OD): δ 8.05 (d, J = 7.5 Hz, 1H, H-6), 7.60 (br s, 2H, Ar-H), 7.14 (d, J = 7.3 Hz, 2H, Ar-H), 6.27 (t, J = 6.5 Hz, 1H, H-1'), 6.03 (d, J = 7.5 Hz, 1H, H-5), 4.37 (dt, J =




3.4, 6.5 Hz, 1H, H-3'), 3.95 (app q, $J_{app} \sim 3.6$ Hz, 1H, H-4'), 3.80 (dd, $J = 3.3, 12.0$ Hz, 1H, H-5'), 3.73 (dd, $J = 3.9, 12.1$ Hz, 1H, H-5'), 2.39 (ddd, $J = 3.8, 6.1, 13.6$ Hz, 1H, H-2'), 2.31 (s, 3H, Me), 2.16 (dt, $J = 6.7, 13.5$ Hz, 1H, H-2'). ^1H NMR (500 MHz, $\text{DMSO}-d_6$): δ 9.62 (br s, 1H, NH), 7.93 (d, $J = 7.5$ Hz, 1H, H-6), 7.63 (br s, 2H, Ar-H), 7.13 (d, $J = 8.2$ Hz, 2H, Ar-H), 6.17 (t, $J = 6.6$ Hz, 1H, H-1'), 5.97 (d, $J = 7.4$ Hz, 1H, H-5), 5.22 (d, $J = 4.2$ Hz, 1H, OH), 4.99 (t, $J = 5.2$ Hz, 1H, OH), 4.24–4.18 (m, 1H, H-3'), 3.79 (app q, $J_{app} \sim 3.5$ Hz, 1H, H-4'), 3.62–3.51 (m, 2H, H-5' and H-5'), 2.26 (s, 3H, Me), 2.16 (ddd, $J = 3.3, 5.8, 13.2$ Hz, 1H, H-2'), 1.97 (dt, $J = 6.6, 13.3$ Hz, 1H, H-2'). HRMS (ESI/TOF) m/z calculated for $\text{C}_{16}\text{H}_{20}\text{N}_3\text{O}_4$ $[\text{M} + \text{H}]^+$: 318.1448, found 318.1443. The ^1H NMR spectrum matches that of the material as reported (Q. Dai, C. Ran, R. G. Harvey, *Tetrahedron*, 2006, **62**, 1764–1771).

Method C (with TASF for synthesis of **20j**, **23a**, and **24**)

To a 0.095 M solution of appropriate nucleoside (1 mol equiv) in dry MeCN at 0 °C, a 1.515 M solution of TASF in dry MeCN (5 mol equiv) was added dropwise and stirred at 0 °C for 1 h. Then the reaction mixture was allowed to stir at room temperature for 16 h. The crude material was concentrated and purified over a short plug silica gel column by eluting with suitable solvent system (see individual compound headings below).


S⁴-Methyl-4-thiothymidine (20j)



The crude material after desilylation was quickly filtered through a short silica plug using 10% MeOH in EtOAc. The filtrate was evaporated and washed with EtOAc followed by 2% MeOH in EtOAc to obtain compound **20j** (18.3 mg, 68%) as a white solid. R_f (SiO_2 /10% MeOH in EtOAc) = 0.49. ^1H NMR (500 MHz, CD_3OD): δ 8.10 (s, 1H, H-6), 6.21 (t, $J = 6.2$ Hz, 1H, H-1'),


4.39 (dt, $J = 4.1, 6.1$ Hz, 1H, H-3'), 3.99 (app q, $J_{app} \sim 3.5$ Hz, 1H, H-4'), 3.85 (dd, $J = 3.0, 12.1$ Hz, 1H, H-5'), 3.76 (dd, $J = 3.7, 12.1$ Hz, 1H, H-5'), 2.54 (s, 3H, SCH₃), 2.46 (ddd, $J = 4.4, 6.1, 13.6$ Hz, 1H, H-2'), 2.17 (dt, $J = 6.6, 13.4$ Hz, 1H, H-2'), 2.10 (s, 3H, Me). ¹³C NMR (125 MHz, CD₃OD): δ 180.3, 156.0, 139.2, 114.1, 89.3, 88.2, 71.6, 62.4, 42.4, 14.1, 13.0. HRMS (ESI/TOF) m/z calculated for C₁₁H₁₆N₂O₄SNa [M + Na]⁺: 295.0723, found 295.0716.

O⁴-Methylthymidine (23a)



Chromatography on a silica gel column by sequential elution with EtOAc and 10% MeOH in EtOAc gave compound **23a** (25.3 mg, 96%) as a white solid. R_f (SiO₂/10% MeOH in EtOAc) = 0.37. ¹H NMR (500 MHz, CD₃OD): δ 8.13 (s, 1H, H-6), 6.24 (t, $J = 6.4$ Hz, 1H, H-1'), 4.38 (dt, $J = 3.8, 6.3$ Hz, 1H, H-3'), 3.97–3.94 (m, 4H, H-4' and OCH₃), 3.84 (dd, $J = 3.1, 12.1$ Hz, 1H, H-5'), 3.75 (dd, $J = 3.7, 12.1$ Hz, 1H, H-5'), 2.41 (ddd, $J = 4.1, 6.2, 13.6$ Hz, 1H, H-2'), 2.15 (dt, $J = 6.6, 13.4$ Hz, 1H, H-2'), 1.97 (s, 3H, Me). ¹³C NMR (125 MHz, CD₃OD): δ 172.5, 158.2, 142.0, 106.6, 89.1, 87.9, 71.7, 62.5, 55.1, 42.2, 12.1. HRMS (ESI/TOF) m/z calculated for C₁₁H₁₆N₂O₅Na [M + Na]⁺: 279.0951, found 279.0948.

O⁴-Methyl-2'-deoxyuridine (24)




Chromatography on a silica gel column by sequential elution with EtOAc and 20% MeOH in EtOAc gave compound **24** (23.7 mg, 95%) as a white solid. R_f (SiO₂/10% MeOH in EtOAc) = 0.20. ¹H NMR (500 MHz, CD₃OD): δ 8.31 (d, $J = 7.4$ Hz, 1H, H-6), 6.23 (t, $J = 6.3$ Hz, 1H, H-1'), 6.07 (d, $J = 7.4$ Hz, 1H, H-5), 4.37 (dt, $J = 3.8, 6.2$ Hz, 1H, H-3'), 3.98 (app q, $J_{app} \sim 3.6$ Hz, 1H, H-4'), 3.92 (s, 3H, OCH₃), 3.81 (dd, $J = 3.2, 12.1$ Hz, 1H, H-5'), 3.74 (dd, $J = 3.8, 12.1$ Hz, 1H, H-5'), 2.45 (ddd, $J = 4.0, 6.1, 13.6$ Hz, 1H, H-2'), 2.15 (dt, $J = 6.6, 13.4$ Hz, 1H, H-2'). ¹³C NMR (125 MHz, CD₃OD):

δ 173.7, 158.2, 145.0, 97.0, 89.2, 88.3, 71.8, 62.5, 54.9, 42.3. HRMS (ESI/TOF) m/z calculated for $C_{10}H_{14}N_2O_5Na$ $[M + Na]^+$: 265.0795, found 265.0805.

General Procedure For Reduction of 3'-Azido nucleosides To Amines (synthesis of 26a-d)

To a solution of the AZT derivative (0.131 mmol, 1equiv.) in dry MeOH (0.6 mL) in a 4 mL vial, 5% Pd/C (27.5 mg) was added. The reaction vial was placed in a two-necked flask to which a hydrogen balloon was attached with via a gas inlet adapter with a Teflon stopcock at one neck and the other neck was stoppered with a rubber septum. The flask was connected to a vacuum line via a needle inserted through the septum. The flask was degassed and filled with H_2 gas via the balloon, and this process was repeated three times. Finally, the reaction was allowed to proceed for 1 h at room temperature under a balloon filled with hydrogen gas. The reaction mixture was filtered through a short plug of Celite and the residue was washed with methanol. The filtrate was evaporated under reduced pressure and washed with EtOAc followed by 5% MeOH in EtOAc. The resulting solid was dried under high vacuum. All the products are very polar materials.


3'-Amino-*N,N*-diethyl-5-methyl-2',3'-dideoxycytidine (26a)



Compound **26a** (38.4 mg, 99%) was obtained as a light-yellow solid. R_f ($SiO_2/MeOH$) = 0.34. 1H NMR (500 MHz, CD_3OD): δ 7.90 (s, 1H, H-6), 6.12 (t, J = 5.4 Hz, 1H, H-1'), 3.89 (dd, J = 2.4, 12.2 Hz, 1H, H-5'), 3.79 (dd, J = 3.2, 12.2 Hz, 1H, H-5'), 3.72 (dt, J = 3.2, 6.7 Hz, 1H, H-4'), 3.62 (q, J = 7.0 Hz, 4H, NCH_2), 3.50 (app q, J_{app} ~ 7.4 Hz, 1H, H-3'), 2.26–2.22 (m, 5H, H-2', H-2', and Me), 1.22 (t, J = 7.0 Hz, 6H, Me). ^{13}C NMR (125 MHz, CD_3OD): δ 165.2, 157.4, 142.7, 104.4, 88.8, 86.7, 61.8,


51.0, 45.0, 42.7, 18.2, 14.1. HRMS (ESI/TOF) m/z calculated for $C_{14}H_{25}N_4O_3$ $[M + H]^+$: 297.1921, found 297.1916.

1-(3-Amino-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(piperidin-1-yl)-2(1H)-pyrimidinone (26b)




Compound **26b** (37.5 mg, 97%) was obtained as a light-yellow solid. R_f (SiO₂/MeOH) = 0.23. ¹H NMR (500 MHz, CD₃OD): δ 7.84 (s, 1H, H-6), 6.12 (t, J = 5.5 Hz, 1H, H-1'), 3.89 (dd, J = 2.6, 12.2 Hz, 1H, H-5'), 3.80–3.69 (m, 6H, H-4', H-5', and NCH₂), 3.49 (app q, J_{app} ~ 7.4 Hz, 1H, H-3'), 2.28–2.20 (m, 5H, H-2', H-2', and Me), 1.96–1.90 (m, 4H, CH₂). ¹³C NMR (125 MHz, CD₃OD): δ 164.0, 157.5, 141.2, 104.8, 88.8, 86.6, 61.9, 51.1, 50.5, 42.6, 26.2, 18.1. HRMS (ESI/TOF) m/z calculated for $C_{14}H_{22}N_4O_3Na$ $[M + Na]^+$: 317.1584, found 317.1598.

1-(3-Amino-2,3-dideoxy- β -D-ribofuranosyl)-5-methyl-4-(pyrrolidin-1-yl)-2(1H)-pyrimidinone (26c)



Compound **26c** (39.9 mg, 99%) was obtained as a white solid. R_f (SiO₂/MeOH) = 0.31. ¹H NMR (500 MHz, CD₃OD): δ 7.98 (s, 1H, H-6), 6.12 (t, J = 5.3 Hz, 1H, H-1'), 3.90 (dd, J = 2.6, 12.3 Hz, 1H, H-5'), 3.80 (dd, J = 3.3, 12.3 Hz, 1H, H-5'), 3.72 (dt, J = 3.2, 6.7 Hz, 1H, H-4'), 3.65–3.58 (m, 4H, NCH₂), 3.49 (app q, J_{app} ~ 7.5 Hz, 1H, H-3'), 2.27–2.22 (m, 2H, H-2' and H-2'), 2.14 (s, 3H, Me), 1.74–1.68 (m, 2H, CH₂), 1.68–1.61 (m, 4H, CH₂). ¹³C NMR (125 MHz, CD₃OD): δ 167.3, 157.6, 143.1, 105.5, 88.9, 86.8, 61.7, 50.9, 49.4, 42.7, 27.3, 25.5, 18.2. HRMS (ESI/TOF) m/z calculated for $C_{15}H_{24}N_4O_3Na$ $[M + Na]^+$: 331.1741, found 331.1744.

1-(3-Amino-2,3-dideoxy-β-D-ribofuranosyl)-5-methyl-4-(morpholin-4-yl)-2(1H)-pyrimidinone (26d)



Compound **26d** (39 mg, 96%) was obtained as a light-yellow solid. R_f (SiO₂/MeOH) = 0.17. ¹H NMR (500 MHz, CD₃OD): δ 8.07 (s, 1H, H-6), 6.11 (t, J = 5.2 Hz, 1H, H-1'), 3.91 (dd, J = 2.3, 12.3 Hz, 1H, H-5'), 3.80 (dd, J = 3.2, 12.3 Hz, 1H, H-5'), 3.76–3.71 (m, 5H, H-4', morpholinyl-CH₂), 3.70–3.65 (m, 4H, morpholinyl-CH₂), 3.49 (app q, J_{app} ~ 7.5 Hz, 1H, H-3'), 2.31–2.21 (m, 2H, H-2' and H-2'), 2.14 (s, 3H, Me). ¹³C NMR (125 MHz, CD₃OD): δ 167.4, 157.4, 143.6, 105.4, 89.0, 87.0, 67.8, 61.6, 50.8, 48.7, 42.7, 17.9. HRMS (ESI/TOF) m/z calculated for C₁₄H₂₃N₄O₄ [M + H]⁺: 311.1714, found 311.1712.

Antiviral activity assays

The synthesized compounds were evaluated against different herpesviruses, including herpes simplex virus type 1 (HSV-1) strain KOS, thymidine kinase-deficient (TK⁻) HSV-1 KOS strain resistant to ACV (ACV^r), herpes simplex virus type 2 (HSV-2) strain G, varicella-zoster virus (VZV) strain Oka, TK⁻ VZV strain 07-1, human cytomegalovirus (HCMV) strains AD-169 and Davis as well as feline herpes virus (FHV), the poxvirus vaccinia virus (Lederle strain), parainfluenza-3 virus, reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro virus, respiratory syncytial virus (RSV), feline coronavirus (FIPV) and influenza A virus subtypes H1N1 (A/PR/8), H3N2 (A/HK/7/87) and influenza B virus (B/HK/5/72), and human immune deficiency virus (HIV-1 and HIV-2). The antiviral assays, other than HIV, were based on inhibition of virus-induced cytopathicity or plaque formation in human embryonic lung (HEL) fibroblasts, African green monkey kidney cells (Vero), human epithelial cervix carcinoma cells (HeLa), Crandell-Rees feline kidney cells (CRFK), or Madin

Darby canine kidney cells (MDCK). Confluent cell cultures in microtiter 96-well plates were inoculated with 100 CCID₅₀ of virus (1 CCID₅₀ being the virus dose to infect 50% of the cell cultures) or with 20 plaque forming units (PFU) and the cell cultures were incubated in the presence of varying concentrations of the test compounds. Viral cytopathicity or plaque formation (VZV) was recorded as soon as it reached completion in the control virus-infected cell cultures that were not treated with the test compounds. Antiviral activity was expressed as the EC₅₀ or compound concentration required to reduce virus-induced cytopathicity or viral plaque formation by 50%. Cytotoxicity of the test compounds was expressed as the minimum cytotoxic concentration (MCC) or the compound concentration that caused a microscopically detectable alteration of cell morphology.

Cytostatic activity against immortalized cell lines

Murine leukemia (L1210), human T-lymphocyte (CEM), human cervix carcinoma (HeLa), and immortalized human dermal microvascular endothelial cells (HMEC-1) were suspended at 300,000–500,000 cells/mL of culture medium, and 100 µL of a cell suspension was added to 100 µL of an appropriate dilution of the test compounds in 200 µL-wells of 96-well microtiter plates. After incubation at 37 °C for two (L1210), three (CEM) or four (HeLa) days, the cell number was determined using a Coulter counter. The IC₅₀ was defined as the compound concentration required to inhibit cell proliferation by 50%.